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Abstract 
 
The prevalence of obesity is dramatically increasing and thus constitutes a major risk 
factor for developing chronic diseases such as type 2 diabetes, dyslipidemia, 
cardiovascular diseases, and certain forms of cancer. High-caloric nutrition and a lack of 
physical activity are the main contributing factors for this global epidemic. Estrogen 
receptors (ERs) are recognized to be involved in many processes related to the control of 
energy homeostasis.  
In my studies, I investigated the impact of estrogens (17beta-estradiol (E2)) on energy 
homeostasis. Special emphasis was given to the effects of two synthetic ER subtype-
selective agonists, 16alpha-LE2 (Alpha) and 8beta-VE2 (Beta), to determine to what 
extend the two distinct ER subtypes are involved in the underlying molecular mechanisms. 
Because of its estrogenic activity and also its widespread use as a nutritional supplement 
the influence of the isoflavone genistein (Gen) was examined. For this purpose two 
different female rat models were used: Wistar rats with nutrition-induced obesity and leptin 
resistant Zucker diabetic fatty (ZDF) rats. In both experiments, the animals were 
ovariectomized (OVX) and treated with vehicle (untreated controls) or the estrogenic 
compounds. 
The most important finding was that treatment of OVX animals with Beta enlarges 
soleus muscle fiber sizes in both animal models compared to untreated OVX animals. 
This anabolic effect may in turn improve the muscle/fat ratio of the body that enhances 
muscular uptake and utilization of fuels. By contrast, in the gastrocnemius muscle of OVX 
ZDF rats substitution with Alpha increased expression and distribution of the insulin-
dependent glucose transporter 4 (GLUT4). Consequently, systemic insulin sensitivity in 
both animal models was improved by treatment with estrogenic compounds compared to 
untreated OVX animals. The strongest effect was observed in E2-treated rats that indicate 
an additive effect through activation of both pathways. 
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In all OVX rats, treatment with either ER subtype-selective agonist showed an anti-
lipogenic effect in adipose tissue, liver, and skeletal muscle of nutrition-induced obese 
Wistar rats in comparison to OVX animals without treatment. Decreased visceral fat mass, 
adipocyte sizes, serum leptin levels, triglyceride accumulation in liver and muscle as well 
as mRNA expression of genes that are involved in lipo-/adipogenesis reflected this. 
Therefore, the lower visceral fat mass as well as decreased accumulation of triglycerides 
in non-adipose tissues such as liver and skeletal muscle most likely contributes to the 
improved insulin sensitivity in such treated animals. 
Gen exerted effects similar to those of the ER beta-selective agonist (except on 
adipose tissue in Wistar rats). Especially, the similar ability to induce anabolic activity in 
the soleus muscle might be highly relevant. Gen-treated animals might have a more 
effective utilization of fuels compared to untreated OVX animals because they showed a 
lower TG content in muscle and liver as well as improved glucose metabolism. 
In conclusion, because of my studies and the fact that ER beta signaling is not 
involved in proliferation of uterus and mammary gland, an effective way to treat obesity 
and co-morbidities in postmenopausal women might be substances that only activate ER 
beta. A combination with physical activity may support the therapy of obesity and co-
morbidities. The isoflavone Gen is able to activate both ER-subtypes. This compound is 
already placed on the market for treatment of postmenopausal complaints, although 
adverse effects of Gen cannot be excluded so far (e.g., increased risk of breast cancer). 
However, Gen might be a natural alternative – not only to the conventional hormone 
replacement therapy, but also as a strategy for treatment of obesity and co-morbidities – 
that deserves further research with respect to these new data. 
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Zusammenfassung 
 
Die dramatisch zunehmende Prävalenz der Adipositas und das damit verbundene Risiko 
für Folgeerkrankungen wie Diabetes mellitus, Hypertonie, Dyslipidämie und koronare 
Herzkrankheiten stellt eine große Herausforderung für das Gesundheitswesen dar. Als 
Hauptursache wird ein chronisches Missverhältnis der Energiehomöostase aufgrund 
permanenter Überernährung und Bewegungsmangel postuliert. Estrogene beeinflussen 
den Glukose- und Lipidstoffwechsel und sind somit in die Regulation des 
Energiehaushaltes involviert. Estrogene vermitteln ihre Effekte über zwei 
Estrogenrezeptor (ER)-Subtypen, den ER alpha und den ER beta. 
Ziel der vorliegenden Arbeit war es mittels tierexperimentellen Studien den Einfluss 
von Estrogenen, speziell 17beta-Estradiol, auf den Energiehaushalt zu untersuchen. Um 
einen tieferen Einblick in die zugrundeliegenden molekularen Mechanismen zu erhalten, 
wurden zwei Subtyp-selektive ER-Agonisten, 16alpha-LE2 (Alpha) and 8beta-VE2 (Beta), 
synthetischer Herkunft eingesetzt. Aufgrund der estrogenen Aktivität und der 
Verfügbarkeit als Nahrungsergänzungsmittel wurde des Weiteren der Einfluss des 
Isoflavons Genistein untersucht. Für die Studien wurden zwei Tiermodelle genutzt: zum 
einen weibliche Wistar-Ratten mit ernährungsinduzierter Adipositas und zum anderen 
weibliche leptinresistente „Zucker diabetic fatty“ (ZDF)-Ratten. Die Tiere wurden 
ovarektomiert (OVX) und entweder mit einem Vehikel (unbehandelte Kontrolltiere) oder 
mit der entsprechenden estrogenen Substanz behandelt. 
Die interessanteste Erkenntnis war, dass im Vergleich zu unbehandelten OVX-Tieren 
beider Tiermodelle die Behandlung mit Beta zur Vergrößerung der Faserquerschnitte im 
Soleusmuskel führte. Dieser anabole Effekt könnte die muskuläre Aufnahme und 
Verwertung von Brennstoffmolekülen verbessern und sich insgesamt positiv auf die 
Körperzusammensetzung auswirken. Den stärksten Effekt hinsichtlich einer erhöhten 
Expression und Translokation des insulinabhängigen Glukosetransporters 4 (GLUT4) in 
die Zellmembran des Gastrocnemiusmuskels zeigte sich dagegen durch die Behandlung 
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von OVX ZDF-Ratten mit Alpha. Im Endergebnis zeigten die Tiere beider Modelle durch 
die Behandlung mit estrogenen Substanzen eine verbesserte systemische 
Insulinsensitivität im Vergleich zu unbehandelten Kontrolltieren. E2-behandelte Tiere 
tolerierten die Glukose am besten und lassen einen additiven Effekt aufgrund der 
Aktivierung beider Signalwege vermuten. 
Im Vergleich zu unbehandelten OVX Wistar-Ratten führte die Behandlung mit E2 oder 
mit jeweils einem der beiden ER-Subtyp-selektiven Agonisten zu einer geringeren 
viszeralen Fettmasse, kleineren Fettzellen, niedrigeren Leptinspiegeln im Serum und 
geringeren Triglyzeridwerten in Leber und Muskel. Auf der Ebene der Genexpression 
waren zudem geringere mRNA-Spiegel von lipo- und adipogenen Genen messbar. Somit 
scheinen beide ER-Subtypen in die antilipogene Wirkung von E2 involviert zu sein. 
Sowohl die reduzierte viszerale Fettmasse als auch die geringere Anreicherung von 
Triglyzeriden in Leber und Muskel tragen sehr wahrscheinlich ebenfalls zur verbesserten 
Insulinsensitivität bei. 
Die Behandlung von OVX Tieren mit Gen führte zu ähnlichen Ergebnissen wie die 
Behandlung mit Beta. Eine alleinige Ausnahme stellte das Fettgewebe dar, da hier eine 
Gen-Behandlung keine antilipogenen/-adipogenen Effekte zeigte. Speziell die Fähigkeit 
von Gen ebenfalls anabol zu wirken, könnte die molekulare Grundlage sein, weshalb 
Gen-behandelte Tiere im Vergleich zu unbehandelten Tiere eine verbesserte Toleranz 
gegenüber Glukose und eine geringere Anreicherung von Triglyzeriden in Muskel und 
Leber zeigten. 
Der ER beta ist nicht in die estrogenvermittelte Proliferation von Uterus und 
Brustdrüse involviert. Vor diesem Hintergrund lassen meine Ergebnisse vermuten, dass 
eine Behandlung mit ER beta-selektiven Substanzen eine effektive Möglichkeit darstellt, 
um Adipositas und deren Folgeerkrankungen in postmenopausalen Frauen zu behandeln, 
ohne deren Risiko für estrogenabhängige Krebsformen zu erhöhen. Eine Kombination mit 
regelmäßiger körperlicher Aktivität könnte die Erfolge bei der Behandlung von Adipositas 
und deren Folgeerkrankungen noch maximieren bzw. eine geringere Dosierung der 
verwendeten Substanz bei gleichbleibendem Behandlungserfolg ermöglichen. Das 
Isoflavon Gen mit seiner Fähigkeit beide ERs zu aktivieren ist eine bereits auf dem Markt 
befindliche Substanz und wird zur Behandlung von postmenopausalen Beschwerden 
eingesetzt, obwohl mögliche negative Effekte (z.B. ein erhöhtes Brustkrebsrisiko) noch 
nicht abschließend geklärt sind. Falls diese Risiken von Gen ausgeräumt werden können, 
könnte diese Substanz eventuell eine kostengünstige Alternative darstellen, um sowohl 
postmenopausale Beschwerden als auch Adipositas und deren Folgekrankheiten zu 
behandeln.  
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Prevalence of obesity and co-morbidities 
 
Obesity is defined as excessive fat enrichment that is mainly accumulated inside the 
abdominal cavity. Its prevalence has nearly doubled between 1980 and 2008 worldwide; 
in some countries of Europe even tripled. According to the WHO, in 2008, nearly 1.5 
billion adults around the world were overweight (BMI greater than 25 kg/m2) – at least 500 
million of them were obese (BMI greater than 30 kg/m2) (WHO, 2012). Since 1990, the 
incidence of overweight individuals among children has steadily increased too. Globally in 
2010, approximately 43 million children under five years were overweight (WHO, 2010).  
Excessive body fat accumulation is now recognized as a major risk factor for serious 
health problems. These include insulin resistance and type 2 diabetes mellitus (T2DM), 
dyslipidemia, and hypertension (a well-documented risk factor for cardiovascular diseases 
like stroke and heart complaints) (Chan and Woo, 2010; Mokdad et al., 2003; Newbold et 
al., 2009; Swinburn et al., 2004). In combination, these disorders are called the metabolic 
syndrome (Eckel, 2011; Miranda et al., 2005). Further, obesity has been identified to 
increase the likelihood for developing certain forms of cancer such as cancers of the colon 
and rectum, breast (postmenopausal), and prostate (Mokdad et al., 2003; Ronco et al., 
2012). Especially in the western world, obesity is stigmatized and thus further results in 
serious social and psychological problems.  
Obesity is attributable mainly to a chronic imbalance of energy homeostasis meaning 
that energy intake exceeds the expenditure caused by high-caloric nutrition combined with 
a more and more sedentary lifestyle (Low et al., 2009; Newbold et al., 2009; Wasan and 
Looije, 2005). However, obesity is often multifactorial in origin, besides physical activity 
and dietary habits genetic and environmental factors contribute to its prevalence 
(Comuzzie et al., 2001; Goulart et al., 2009).  
Meanwhile, obesity and co-morbidities affect all ages, sexes, races, and socio-
economic groups and are therefore responsible for constantly rising health costs and 
premature death. Therefore, it is not exaggerated to say that prevention and therapy of 
obesity is one of the greatest public health challenges of our century. Thus, more scientific 
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knowledge about the underlying physiological causes of obesity is of fundamental 
importance. 
 
 
Central regulation of energy homeostasis 
 
Energy homeostasis means a well-balanced intake and expenditure of energy that is 
strictly controlled via the hypothalamus by hormonal signaling. There are varieties of 
peripheral signals that inform the central nervous system (CNS) about the energy state of 
the body. “Immediate” signals are released from the gastrointestinal tract in response to 
the presence of food (e.g., ghrelin as a hunger-stimulating hormone and peptide YY or 
Cholecystokinin (CCK) as mediators of satiation). As a “longer-term” signal, leptin is 
secreted by adipose cells and thus also referred to as “adipositiy” signal. After crossing 
the blood-brain barrier, these hormones act on several hypothalamic areas including the 
arcuate nucleus, the paraventricular nucleus, the lateral hypothalamus, the dorsomedial 
hypothalamus, and the ventromedial hypothalamus. In particular, the arcuate nucleus 
houses two types of neurons - AgRP/NPY and POMC/CART neurons – that play a key 
role in regulation of energy intake and expenditure. The first subpopulation of neurons 
releases the neuropeptids agouti-related protein (AgRP) and neuropeptide Y (NPY). The 
second population secretes alpha melanocyte stimulating hormone (α-MSH), a 
posttranslational derivative of proopiomelanocortin (POMC), and cocaine- and 
amphetamine regulated transcript (CART). Neuronal projections from these two types of 
neurons enable communication with other hypothalamic areas. Agrp and Npy are referred 
to as orexigenic hormones, because they stimulate food intake and decrease energy 
expenditure. α-MSH and CART in turn inhibit food intake and increase energy expenditure 
and referred to as anorexigenic hormones (Barsh and Schwartz, 2002; Gale et al., 2004; 
Morton et al., 2006; Schwartz, 2001; Simpson et al., 2009). 
Leptin appears to be crucial to maintain the individual body weight/fat within certain 
limits through negative feedback regulation between adipose tissue and the brain. This 
hormone serves as an index of body energy storage, because circulating leptin levels 
correlate strongly to the whole body fat stores. In normal physiology, increased fat mass 
leads to an elevated leptin level, which in turn restricts appetite and increases energy 
expenditure, and vice versa (Gale et al., 2004; Morton et al., 2006; Schwartz, 2001; 
Simpson et al., 2009). 
Insulin, synthesized by pancreatic beta cells, has been shown to have properties 
similar to leptin in the brain. Like leptin, it also crosses the blood-brain barrier, where it 
inhibits food intake and stimulates energy expenditure by acting on the hypothalamus. 
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Unlike leptin, insulin is secreted acutely in response to food intake, but it is believed that 
prolonged high levels of insulin may induce leptin secretion (Gale et al., 2004; Schwartz, 
2001). 
Whereas normal-weight individuals are protected against excessive body weight 
gain/loss, homeostatic control is impaired in obesity. The vast majority of obese 
individuals do not respond to their extremely high serum levels of leptin. This physiological 
phenomenon is referred to as leptin resistance. Moreover, obesity is associated with both 
leptin and insulin resistance (Gale et al., 2004; Morton et al., 2006). 
 
 
Peripheral regulation of fuel molecules 
 
Liver, skeletal muscle and adipose tissue (in particular the visceral fat) are highly 
metabolically active tissues.  
The liver plays a central role in supplying the brain, the muscles, and other peripheral 
organs with fuels. The majority of all nutrients that are absorbed from the gastrointestinal 
tract enter the liver through the blood stream (triglycerides packaged in chylomicrons, 
glucose, and amino acids). Here they undergo various chemical processes triggered by 
several hormones that enable their immediately utilization (energy demand of the liver), 
storage (for later use during food scarcity) or export (fuel supply) (Stryer, 1994).  
The skeletal muscle supports the skeleton enabling movement of the body by muscle 
contraction. For all forms of muscle work, but also at rest, adenosine triphosphate (ATP) 
needs to be provided. Storage of this energy-rich compound is limited. Therefore, main 
types of fuel to produce ATP are free fatty acids (FFA) and glucose that can be stored in 
significant amounts within the muscle as triglycerides and glycogen, respectively (Atalay 
and Hänninen, 2009). 
An important function of adipose tissue is the storage of energy as lipids. During 
periods of food abundance adipocytes ingest excess fuel molecules, convert them into 
triglycerides, and stores them in intracellular lipid droplets. During periods of food scarcity 
stored triglycerides are broken down into FFA and glycerol, which then are released into 
the blood. In muscle, FFA serve as fuel to produce ATP. In liver, FFA and glycerol are 
used for synthesis of ketone bodies and glucose or they participate in hepatic TG 
production (Anghel and Wahli, 2007). 
 
With respect to the metabolism of lipids, the liver is the key tissue in manufacturing (de 
novo lipogenesis) or importing FFA from the blood. Within the liver, FFA are synthesized 
to triglycerides that can be stored as lipid droplets or incorporated into VLDL for transport 
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via blood. In the blood stream, triglyceride content of these particles is progressively 
reduced by the lipoprotein lipase, an enzyme that is attached at the endothelial surface in 
capillaries. With this process the composition of the molecule changes – the triglyceride 
content decreases relatively to cholesterol – and VLDL becomes IDL and later on LDL. 
Released lipids can enter the cell for storage (adipose tissue) or energy production 
(muscle) (Anghel and Wahli, 2007). 
With respect to the metabolism of glucose, the central organ is also the liver that 
ensures adequate blood glucose supply. The liver is the only organ that – depending on 
requirements – can both store and release glucose into the blood for use by other tissues. 
This is of great importance for certain tissues like brain and red blood cells that exclusively 
use glucose as energy source. The liver uses three metabolic processes to manage 
glucose: 
1. glycogenesis - excess glucose is converted to glycogen for storage within the liver,  
2. glycogenolysis - to raise blood glucose levels the liver breaks down stored 
glycogen, and  
3. gluconeogenesis - when glucose is low and the deposit of glycogen is exhausted 
the liver is able to synthesize glucose from lactate and alanine (derived from 
muscle) or glycerol (derived from adipose tissue).  
Skeletal muscle is the major source of stored glycogen. Depending on muscle mass 
and nutrative state up to three quarter of body glycogen is stored in myocytes. Especially 
during moderate and intensive exercise, glucose (derived from glycogen by 
glycogenolysis) is the major supply of energy. In contrast to hepatocytes, myocytes lack 
the enzyme glucose-6-phosphatase that is necessary to release glucose into the blood. 
Therefore, glucose that once entered into myocytes must be used ore stored within the 
cells. 
Also the adipose tissue participates in the regulation of glucose homeostasis. Via the 
glycolytic pathway, adipocytes are involved in glucose disposal like liver and muscle. 
Within the tissue, glucose provides the substrate for de novo synthesis of FFA and 
glycerol. Important, released FFA by adipocytes into the circulation influence the 
sensitivity of liver and muscle to glucose (Stryer, 1994). 
 
Hormonal signaling is essential in the peripheral regulation of fuel metabolism. Insulin but 
also glucagon, adrenaline, and noradrenaline play an important role in mobilization and 
storage of fuels.  
Insulin is released in response to enhanced levels of glucose and hormones of the 
gastrointestinal tract (gastrin, secretin, and incretins). Like in the brain, insulin serves as 
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an index of satiety to peripheral tissues. After binding to its receptor several signaling 
pathways are activated resulting in physiological effects as follows: 
1. Insulin promotes glucose uptake by translocation of glucose transporters to the cell 
membrane. Two isoforms, which are regulated by insulin, are important in this 
context – GLUT2 (expressed in liver and pancreas) and GLUT4 (expressed in 
skeletal muscle and adipose tissue). By contrast, glucose uptake occurs also 
insulin-independent (e.g., via GLUT1 in the brain). 
2. Insulin accelerates glycolysis in liver, muscle, and adipose tissue, which in turn 
promotes enhanced fatty acid synthesis. 
3. Insulin increases glycogen synthesis and decreases glycogenolysis in liver, 
skeletal muscle, and adipose tissue. 
4. Insulin decreases gluconeogenesis in liver. 
5. Insulin enhances uptake of blood lipids into muscle and fat tissue and induces fatty 
acid and triglyceride synthesis. 
6. Insulin inhibits lipolysis in adipose cells, which results in lowered serum FFA 
levels. 
7. Insulin inhibits fatty acid oxidation in liver and skeletal muscle. 
8. Insulin promotes amino acid uptake into tissues, which in turn increases the rate of 
protein synthesis. 
9. Insulin inhibits protein degradation at least in muscle.  
In general, low levels of insulin reverse the above-described effects. Thus, insulin 
promotes anabolic processes by inhibiting catabolic ones (Dimitriadis et al., 2011; Stryer, 
1994). 
Glucagon, secreted by pancreatic alpha cells, has opposite effects compared to 
insulin. Glucagon stimulates glycogenolysis and gluconeogenesis, inhibits glycogenesis 
and glycolysis, decreases synthesis of fatty acids, and promotes the mobilization of 
triglycerides in adipose cells (Stryer, 1994). 
 
Deregulation of lipid metabolism is associated with excessive fat enrichment in adipose 
tissue but also elevated accumulation of triglycerides in liver and muscle and strongly 
correlates with obesity and peripheral insulin resistance. Further, increased hepatic 
triglyceride accumulation is accompanied by over production of VLDL and is believed to 
be one key metabolic disturbance that results in a dyslipidemic profile (characterized by 
increased serum VLDL, LDL, and triglycerides combined with decreased HDL), which 
represents in turn a major risk factor of developing several cardiovascular diseases (Fon 
Tacer and Rozman, 2011). 
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Deregulation of glucose metabolism is caused primarily through disturbed insulin 
production/secretion (T1DM) or impaired insulin sensitivity of the tissues (T2DM). In both 
cases insulin-dependent glucose uptake in tissues is ineffective. Consequently, glycolysis 
is inhibited in all tissues, gluconeogenesis is stimulated in liver, lipolysis is increased in 
adipose cells, and protein degradation is enhanced in muscle. Overall, this means that 
primarily lipids and proteins serve as energy source, while glucose remains in the blood 
stream triggering pathological changes in blood vessels (Stryer, 1994). Obesity is strongly 
associated with T2DM. 
A combination of disorders like insulin resistance, dyslipidemia, obesity, 
cardiovascular diseases are called the metabolic syndrome (Miranda et al., 2005).  
 
 
Estrogen signaling 
 
In both males and females, estrogens are crucial for normal development and 
maintenance of sexual and reproductive function. The three major naturally occurring 
estrogens are estrone (E1), estradiol (E2), and estriol (E3), whereby estradiol is the 
biologically most active form (Heldring et al., 2007; Kuiper et al., 1997). Estradiol is the 
predominant estrogen during the reproductive phase of females and the developing 
follicles in the ovaries are the primary source. The estrogen biosynthesis starts in the 
theca interna cells of the ovaries with the synthesis of pregnenolone and progesterone 
from cholesterol. These substances serve as precursors for the synthesis of androgens, 
which requires several enzymatic steps. The final step is catalyzed by the enzyme 
aromatase that converts androgens into estrogens (Löffler and Petrides, 2003). Estriol is 
produced in large amounts by the placenta during pregnancy, whereby estrone dominates 
in postmenopausal females. In males and postmenopausal females the principles sites of 
estrogen secretion are the adrenal cortex and adipose tissue. Extragonadal estrogen 
biosynthesis occurs further in bone, brain, and vasculature. In males, also the Leydig cells 
of the testes produce small amounts of estrogens. However, the adipose, brain, and bone 
are able to convert androgens into estrogens by aromatase, but they do not synthesize 
androgenic precursors from cholesterol. Hence, estrogenic production in adipose, brain, 
and bone depends on circulating androgens (Simpson et al., 1999; Simpson et al., 2005). 
Cellular signaling of estrogens is mediated via two distinct estrogen receptors (ERs), 
ER alpha and ER beta, which belong to the nuclear receptor (NR) family of transcription 
factors. Both receptors are located at different chromosomal segments as well as have 
tissue and gender specific expression patterns. Whereas the ER alpha is expressed 
primarily in the uterus, kidney, heart, and liver, the ER beta expression is predominant in 
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the ovary, prostate, gastrointestinal tract, bladder, lung, and hematopoietic and central 
nervous systems. Some tissues express both ER subtypes, i.e., the mammary gland, 
epididymis, adrenal, skeletal muscle, adipose tissue, thyroid, bone, and certain regions of 
the brain. Coexpression of ER alpha and beta in the same cell type is described for 
several neurons in the brain and thymocytes as well as in skeletal muscle and adipose 
tissue (Barros et al., 2009; Enmark et al., 1997; Hillisch et al., 2004; Matthews and 
Gustafsson, 2003; Nilsson et al., 2001).  
Like many other members of the NR family, ERs are composed of functionally distinct 
domains. The N-terminal domain contains the ligand-independent activation function 1 
(AF1) which enables the modulation of target gene expression through direct interaction 
with coactivators/corepressors or other components of the transcription machinery. A 
second ligand-dependent activation function (AF2) is harbored in the ligand-binding 
domain (LBD) at the C-terminus. This domain is involved in ligand binding, receptor 
dimerization, nuclear translocation, and transactivation of target gene expression by 
interaction with coregulatory proteins. Unlike the N-terminal regions of ER alpha and ER 
beta, which vary strongly in sequence and length, the LBDs are relatively high conserved. 
Although the AF1 revealed transcriptional activity in the absence of AF2, the full ER 
activity is believed to be reached when the two AFs act in a synergistic manner. Further, 
the AF1 of ER alpha is more active compared to the activity of the AF1 domain of ER beta 
and the transcriptional activity of each AF depends on cell type and promoter 
characteristics. Between the two domains at the N- and C-terminus, there are two other 
regions, which are referred to as the DNA-binding domain (DBD) and the hinge-domain. 
The DBD contains two zinc finger motifs, which is essential for receptor dimerization and 
specific binding to estrogen responsive elements (ERE) in the regulatory regions of 
estrogen target genes. This domain represents the highest degree of sequence homology 
and therefore the specificity and affinity to bind to various EREs is similar for both the ER 
alpha and beta. Finally, the hinge domain of the two ER subtypes shows low 
conservation, harbors a nuclear localization signal, and contributes to flexibility between 
receptor and DNA (Enmark and Gustafsson, 1999; Heldring et al., 2007; Nilsson et al., 
2001; Zhao et al., 2008). 
ERs exert their large variety of actions by using different molecular pathways. There 
are the direct (classical) and indirect pathways which start with ligand-dependent ER 
activation followed by homo- or hetero-dimerization of those receptors. ER dimers then 
bind either to EREs on DNA (direct pathway) or interact with other transcription factors 
such as SP1, AP1, and NFκB (indirect pathway), but both variants finally result in 
modulation of gene expression. Another genomic pathway is ligand-independent. In this 
case, ERs interact with other signaling pathways (i.e., several growth factors and 
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neurotransmitters), whereby ERs become phosphorylated by activated kinases that 
subsequently lead to ER activation and dimerization, DNA-binding, and gene regulation. 
In addition, activated ERs are also able to mediate non-genomic effects, which occur 
rapidly within seconds or minutes. These rapid effects involve the activation of several 
signaling cascades such as protein kinase A and C, and activated mitogen-activated 
protein kinase, which in turn affect ion channel fluxes or lead to other cellular responses. 
Apart from the classical ER alpha and beta, also a membrane-associated receptor (G 
protein-coupled receptor) may be involved in the rapid pathway. This receptor was 
identified in the last few years and might be able to mediate a response to E2 too (Cenni 
and Picard, 1999; Heldring et al., 2007; Nilsson et al., 2001). 
Although the overall homology of the LBDs between the ER alpha and beta is 
relatively high, the binding cavities of the two ER subtypes differ clearly in size and 
flexibility. The endogenous estrogens show overall a quite similar binding affinity for both 
ERs, but there is a range of other ligands of natural or synthetic origin for which the two 
ER subtypes exhibit different affinities. Further, the interaction of such estrogenic 
compounds with the binding cavities of the ERs may result in an agonistic or antagonistic 
effect, whereby in turn such agonistic/antagonistic properties can be restricted to specific 
tissues or cell types apparently dependent on the co-factors that are expressed and 
recruited in the respective tissues. In these cases, the estrogenic compounds are referred 
to as selective estrogen receptor modulators (SERMs) (Heldring et al., 2007; Hillisch et 
al., 2004; Kuiper et al., 1997). Examples of compounds with tissue specific estrogenic 
activity are Tamoxifen and Raloxifen. Both substances act as an ER agonist in uterus and 
bone, but show ER antagonist activity in the breast, therefore these synthetic SERMs 
have been used for therapy of breast cancer and osteoporosis for several years (Diel, 
2002; Ohmichi et al., 2005; Wade and Heller, 1993). Therefore, it is difficult to predict the 
magnitude and direction of an estrogenic response, because both the binding affinity of a 
ligand but also the cellular/nuclear context in which the ligand acts enable a wide range of 
combinations to modulate a physiological response to E2 or other ligands.  
Another interesting compound with affinity to ERs is the isoflavone genistein (Gen). 
This compound is also referred to as a phytoestrogen. Based on its chemical structure 
Gen can activate both ER subtypes, but has a higher binding preference to ER beta than 
to ER alpha (Kuiper et al., 1998). Genistin, the glycoside of Gen, and Gen itself are 
natural compounds of various plants and are primarily absorbed from food. Soybeans and 
soy-derived food items or supplements constitute the main source for humans. In the 
intestine, both microbial enzymes and endogenous phase II enzymes metabolize soy 
isoflavones, whereby the individual microbial flora influences the quality and quantity of 
metabolites. Compared to Western countries people in Asia are highly exposed to Gen, 
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because the traditional diet is rich in soy and soy products (Orgaard and Jensen, 2008). 
However, nowadays genistin and its aglycone Gen can be found in dietary supplements. 
Therefore, also people in Western countries may be highly exposed to these isoflavones. 
Beside its ability to bind on ERs, Gen at higher doses is also known to produce non-
hormonal effects (e.g., inhibition of several tyrosine kinases (Akiyama et al., 1987; 
Elmarakby et al., 2011), AMPK activation (Arunkumar and Anuradha, 2012), epigenetic 
changes (Li et al., 2009; Molinie and Georgel, 2009), and inhibition of inflammation 
(Valsecchi et al., 2011).  
To discriminate whether an E2-induced physiological process is ER alpha-mediated, 
ER beta-mediated or both, ligands that selectively bind to only one of the two ER subtypes 
as well as ERKO animals that only express either subtype (αERKO or βERKO) are 
available. Examples of ER subtype-selective agonists and important for the presented 
work are the ER alpha-selective agonist 16alpha-LE2 (Alpha) and the ER beta-selective 
agonist 8beta-VE2 (Beta). Both substances are steroidal in origin and were designed 
based on the protein structure and the existing differences in size and flexibility of both ER 
ligand-binding cavities (Hillisch et al., 2004). In addition, such substances with high affinity 
to only one of both ER subtypes provide new therapeutic concepts for several diseases. 
 
 
Impact of estrogen receptors on energy homeostasis 
 
Beside their enormous impact on growth and development of the reproductive tract and 
maintenance of reproductive function, the two ER subtypes are involved in the regulation 
of a wide range of biological processes in the whole body. For example, these processes 
include the function of the cardiovascular, the immune, and the central nervous system, 
but also diverse processes that are related to energy homeostasis. At present, particularly 
the influences of estrogens on energy intake and expenditure as well as lipid and glucose 
metabolism are being intensively investigated in humans and rodents. For example, the 
enormous decline of endogenous estrogens in women during menopausal transition is 
associated with body weight gain. Additionally, body weight gain is combined with an 
unfavorable change of the body composition (higher fat/muscle ratio) and leads in turn to 
a higher incidence of visceral obesity, insulin resistance, and T2DM (Curtis and Wilson, 
2005; Kristensen et al., 1999; Ley et al., 1992; Louet et al., 2004; Rolland et al., 2007; 
Toth et al., 2000a). Numerous clinical studies have investigated the effect of hormone 
replacement therapy (HRT) on postmenopausal women. The outcomes have shown a 
decrease of central obesity, lower incidence of T2DM, increased sensitivity towards 
glucose and insulin, and an improvement in lipid metabolism (Andersson et al., 1997; 
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Curtis and Wilson, 2005; Kanaya et al., 2003; Pentti et al., 2009; Samaras et al., 1999; 
Santen et al., 2010). Also men display a higher prevalence of visceral obesity and 
impaired glucose metabolism, when compared with premenopausal women (Kuhl et al., 
2005). Similar effects were observed in several animal models. Ovariectomy in rodents 
led to body weight gain and the development of obesity (Hertrampf et al., 2006a; 
Hertrampf et al., 2008b; Naaz et al., 2002) as well as to dyslipidemia and impaired 
glucose and insulin tolerance (Riant et al., 2009; Saengsirisuwan et al., 2009). Treatment 
with E2 antagonized these effects. Moreover, also aromatase-knockout mice were 
described to develop glucose intolerance and insulin resistance (Simpson et al., 2005; 
Takeda et al., 2003).  
Beside the impact of estrogens receptors on energy homeostasis alone, the 
interaction of estrogens and physical activity regarding this issue are of great importance, 
because obesity mainly results from chronic energy imbalance caused by both increased 
intake and decreased expenditure of energy (Low et al., 2009; Newbold et al., 2009; 
Wasan and Looije, 2005). Therefore, physical activity as a key determinant to increase 
energy expenditure is obvious. Consequently, it is not surprising that the beneficial effect 
of exercise in prevention or therapy of obesity and co-morbidities has been proven before 
many times (Eriksson and Lindgarde, 1991; Hamman et al., 2006; Knowler et al., 2002; 
Lindstrom et al., 2006; Pan et al., 1997; Wing, 2010). The described beneficial effects of 
exercise includes weight loss by catabolising body fat that results in a more favorable 
body composition and a lower risk of developing insulin resistance and cardiovascular 
diseases. However, studies that focus on the interaction of estrogens and physical activity 
regarding energy metabolism in females are limited. This issue is not only relevant for 
young individuals but also for women after menopause with HRT. Recently, two animal 
studies using female wistar rats on a high fat diet were conducted in our laboratory, which 
evaluated the effect of E2 in combination with physical activity on both prevention and 
therapy of obesity (Zoth et al., 2010; Zoth et al., 2012)1. The outcomes of the studies 
showed that regular exercise training, performed in OVX rats for six weeks, results in 
effects that were similar to those of E2 treatment alone. The observed effects covered 
body weight and body fat reduction as well as improved glucose metabolism (at lest in 
tendancy compared to sedentary OVX rats without E2 treatment). A combination of 
exercise training and E2 treatment showed the strongest effect in prevention and therapy 
of obesity. 
Both, selective ER subtype-selective agonists and ER knockout animals (as 
mentioned above) were used to determine the impact of the two distinct ER subtypes in 
                                                 
1
  Both studies were performed with my colleague Dr. Nora Zoth at the German Sports University. This work 
has already been used for her dissertation and is therefore not subject to the work presented here. 
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the beneficial role of estrogens on metabolism. In general, to date the metabolic role of 
ER alpha is better investigated than the role of ER beta, because most studies so far 
focused on the ER alpha subtype. For example, several animal experiments revealed that 
the ER alpha is responsible for diminished body weight gain in both sexes (Bryzgalova et 
al., 2006; Cooke et al., 2001; Heine et al., 2000; Hertrampf et al., 2008a; Hertrampf et al., 
2008b). Improved tolerance towards glucose and insulin was shown by using ERKO mice 
and wild type counterparts. αERKO mice revealed increased hepatic lipogenesis 
(Bryzgalova et al., 2006), decreased GLUT4 expression in skeletal muscle and white 
adipose tissue (Barros et al., 2009; Barros et al., 2006) as well as a higher rate of 
pancreatic beta-cell apoptosis (Le May et al., 2006) when compared to wild types. 
However, the role of ER beta on E2 regulation of energy homeostasis is less clear and 
somewhat controversial. For example, there are studies showing that the lack of ER beta 
result in an obese phenotype (Foryst-Ludwig et al., 2008; Seidlova-Wuttke et al., 2012), 
whereas other studies do not show this effect (Cooke et al., 2001; Faulds et al., 2012; 
Nilsson and Gustafsson, 2011). Similar inconsistent results exist regarding glucose 
homeostasis. βERKO mice were described to show significant improved glucose 
tolerance (Barros et al., 2009; Foryst-Ludwig et al., 2008) but also to tolerate glucose on a 
similar level as wild types (Bryzgalova et al., 2006). Therefore, further investigations are 
needed to understand the metabolic role of ER beta. In general, the molecular pathways 
that are activated by the two distinct ER subtypes are not completely resolved. 
 
 
Objectives of the work 
 
The overall aim of my studies was to evaluate the role of E2 on energy metabolism, 
especially what occurs when the primary function of the ovaries has ceased. Special 
emphasis was given to the effects of the ER subtype-selective agonists Alpha and Beta. 
Additionally, the impact of the phytoestrogen Gen was investigated because of its 
estrogenic activity and the controversial discussion concerning its impact on energy 
homeostasis. Finally, the effect of E2 in combination with physical activity on prevention 
and therapy of obesity was evaluated. 
For this purpose two animal experiments using female rats were performed. In 
general, the rats were ovariectomized (OVX) to stop the primary endogenous estrogen 
production or SHAM-operated. Subsets of OVX rats were treated with E2, Alpha, Beta, or 
Gen.  
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The thesis addresses the following research questions that will be discussed in detail 
in the later chapters. 
 
CHAPTER TWO 
 How does E2 treatment influence parameters that are related to energy 
homeostasis in healthy Wistar rats with nutrition-induced obesity? 
 To what extent are the two distinct ER subtypes, ER alpha and ER beta, involved 
in the action of E2? 
 Can the application of Gen induce effects similar to those of E2? 
 
CHAPTER THREE 
 What are the underlying molecular mechanisms responsible for the observed 
effects of treatment with Alpha, Beta, or Gen in chapter two? 
 
CHAPTER FOUR 
 To what extent are the both ER subtypes responsible for the existing gender 
dimorphism regarding glucose metabolism in obese leptin resistant Zucker diabetic 
fatty (ZDF fa/fa) rats? 
 
 
 
 
 
 
 
 
 
Chapter Two 
 
 
 
Impact of estradiol, ER subtype-selective agonists and genistein on 
energy homeostasis in a rat model of nutrition-induced obesity 
 
 
 
 
 
 
 
 
 
 
 
 
This study has been published as: 
Carmen Weigt, Torsten Hertrampf, Nora Zoth, Karl Heinrich Fritzemeier, Patrick Diel. 
Molecular and Cellular Endocrinology 2012; 351 (2): 227–238. 
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Abstract 
 
Estrogens are known to be involved in the control of energy homeostasis. Here, the role of 
ER alpha and ER beta in a model of nutrition-induced obesity was investigated. 
Ovariectomized Wistar rats were fed with a high fat diet and received either vehicle, E2, 
ER subtype-selective agonists (Alpha and Beta), or Genistein. After 10 weeks, body 
weight, visceral fat, serum levels of leptin and lipids, and in the skeletal muscle anabolic 
markers were determined. Treatment with E2 and Alpha decreased body weight, total 
cholesterol, and VLDL. In contrast, visceral fat mass, adipocyte size, and serum leptin 
were reduced by E2, Alpha, and Beta. In the soleus muscle, treatment with E2 and Beta 
modulated Igf1 and Pax7 gene expression and resulted in larger muscle fibers. 
The data indicate that blood lipids are affected via ER alpha, whereas activation of ER 
beta results in an increase of soleus muscle mass. Adipose tissue homeostasis seems to 
be affected via both ERs.  
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Introduction  
 
Obesity, defined as a BMI greater than 30 kg/m2 in adults, has been identified as a major 
risk factor for chronic diseases, including type 2 diabetes, insulin resistance, dyslipidemia, 
hypertension, cardiovascular disease, coronary heart disease, liver and gall bladder 
diseases and certain forms of cancer (Chan and Woo, 2010; Mokdad et al., 2003; 
Newbold et al., 2009; Swinburn et al., 2004). Already in 1997, the WHO formally 
recognized obesity as a global epidemic (Caballero, 2007). In 2005, approximately 1.6 
billion adults (age 15+) around the world were overweight (BMI greater than 25 kg/m2) - at 
least 400 million of them were obese, and these numbers will continue to rise (Chan and 
Woo, 2010; Low et al., 2009).  
Obesity is most likely caused by a combination of genetic, behavioral, and 
environmental factors (Comuzzie et al., 2001; Goulart et al., 2009). However, the main 
reason of this epidemic rapid growth of obesity and overweight over the last several 
decades is thought to be a chronic imbalance of energy homeostasis. This chronic 
imbalance is attributed to increased consumption of higher energy-dense and nutrient-
poor foods with high levels of saturated fats and sugar combined with reduced 
opportunities to use physical energy (Low et al., 2009; Newbold et al., 2009; Wasan and 
Looije, 2005). 
Meanwhile, obesity affects virtually all ages, sexes, races and socioeconomic groups, 
and therefore poses a serious social and psychological problem. The loss of circulating 
estrogen in postmenopausal women is associated with body weight gain and increased 
abdominal fat mass (Kristensen et al., 1999; Ley et al., 1992; Toth et al., 2000a). Similar 
observations were done in different animal models. Ovariectomy in mice, rats, and Syrian 
hamster resulted in body weight gain and the development of obesity, whereas treatment 
with E2 antagonized these effects (Hertrampf et al., 2006a; Hertrampf et al., 2008b; Naaz 
et al., 2002; Wade and Powers, 1993). In the meantime, it is well known, that estrogens 
directly influence energy homeostasis through modulation of glucose and lipid metabolism 
(Ropero et al., 2008). 
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Cellular signaling of estrogens is mediated via two distinct ERs, ER alpha and ER 
beta, which belong to the nuclear receptor family of transcription factors. Both receptors 
are located at different chromosomal segments and have tissue as well as gender specific 
expression patterns. Like many other members of the nuclear receptor family, ERs are 
consisted of functionally distinct domains. ER alpha and ER beta differ considerably in 
their three-dimensional structure of the ligand-binding domain, representing the key 
requirement for SERMs (Heldring et al., 2007; Kuiper et al., 1997). Therefore, the binding 
affinity of the ligand as well as the cellular/nuclear context in which the ligand acts, enable 
a wide range of combinations to modulate a physiological response to E2 or other 
potential ligands (Diel, 2002; Ohmichi et al., 2005).  
To evaluate the role of the ERs in both disease and normal physiology, especially to 
answer the question of which physiological process is ER alpha-mediated, ER beta-
mediated or both, subtype-selective ER agonists offer an important tool. Highly subtype-
selective and steroidal ER agonists 16alpha-LE2 (Alpha) and 8beta-VE2 (Beta) were 
designed based on the protein structure and the existing differences in size and flexibility 
of both ligand-binding cavities of ER alpha and ER beta. In vitro studies using radio ligand 
competition and transactivation assays showed that 16alpha-LE2 binds to ER alpha and 
8beta-VE2 binds to ER beta selectively (~200 fold), but with similar potency to E2 (Hillisch 
et al., 2004). Animal experiments using these compounds confirmed the selective 
stimulation of either ER alpha or ER beta. ER alpha mediated effects of E2 include uterus 
proliferation, inhibition of cardiac hyperthrophy, protection of bone mineral density, 
increased movement drive and body weight control (Hertrampf et al., 2007; Hertrampf et 
al., 2008a; Hertrampf et al., 2008b; Hillisch et al., 2004; Pelzer et al., 2005). Metabolic 
studies using αERKO animals revealed that ER alpha absence caused increased white 
adipose tissue content, insulin resistance, and impaired glucose tolerance in both sexes 
(Heine et al., 2000). The role of ER beta in E2 regulation of energy homeostasis is less 
clear and somewhat controversial. Other interesting compounds with affinity to ERs are 
plant derived. For example, the isoflavones Gen and Daidzein can activate both ER 
subtypes based on their chemical structure, but have greater binding affinity to ER beta 
than for ER alpha (Kuiper et al., 1998). 
Because tissues involved in the control of energy homeostasis such as adipose 
tissue, pancreatic tissue, skeletal muscle, and brain express both ER alpha and ER beta, 
it is of interest to determine to what extent ERs are involved in the underlying molecular 
mechanisms to develop more specific treatment strategies for obesity and diabetes in the 
future.  
Thus, the aim of this study was to investigate the impact of E2, the ER subtype-
selective agonists Alpha and Beta, and Gen on energy homeostasis in a rat model of 
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nutrition-induced obesity. For this purpose, juvenile OVX Wistar rats on a HF diet were 
treated with E2, Alpha, Beta, and Gen for 10 weeks. The SHAM and untreated OVX 
animals as well as the LF diet served as controls. After the experimental period, the 
effects of the different diet and substances on energy intake, body weight, visceral body 
fat mass, serum levels of leptin and blood lipids as well as on the soleus muscle were 
investigated. 
 
 
Materials and methods 
 
Animals 
Juvenile female Wistar rats (6-weeks old, 120–150g) were obtained from Janvier (Janvier, 
Le Genest St Isle, France) and kept at constant room temperature (20 °C ± 1), relative 
humidity (50–80%) and illumination (12-h light/dark cycles). The animals were housed 3–4 
in each cage, with food (SSniff GmbH, Soest, Germany) and water provided ad libitum. All 
animal procedures were approved by the Committee on Animal Care and compliant with 
accepted veterinary medical practice.  
 
Animal treatment and diet 
Prior to experimental exposure procedures, all animals were ovariectomized (OVX) or 
SHAM operated via the dorsal route. Following two weeks of regeneration and 
endogenous hormonal decline, the animals were randomly allocated to different treatment 
and diet groups (n=7). Two different diets were used, a phytoestrogen free LF diet (ssniff® 
EF D12450B* (I) mod. LS* containing a metabolizable energy of 15.0 MJ/kg) and a 
phytoestrogen free HF diet (ssniff® EF R/M acc. D12451 (I) mod.* containing a 
metabolizable energy of 19.2 MJ/kg). All SHAM animals and a subset of OVX animals 
were fed with the LF diet or the HF diet. The remaining OVX animals received the HF diet 
and were treated with E2, Alpha, Beta or Gen (composition of diets and animal grouping 
see table 1 and Fig. 1). E2 (4µg/kg b. wt per day), Alpha (10 µg/kg b. wt per day), and 
Beta (100 µg/kg b. wt per day) were applied via ALZET® osmotic mini pumps, whereby 
the substances were dissolved in dimethylsulfoxide and water according to the 
manufacturer’s instructions for filling. Gen was administered via Gen-enriched food (700 
mg/kg HF diet resulting in approx. 42 mg/kg b. wt per day). Ssniff Spezialdiäten GmbH, 
Soest, Germany, did the food enrichment with Gen. The treatment doses of the respective 
substances were chosen based on previous experiments (Diel et al., 2004; Hegele-
Hartung et al., 2004; Hertrampf et al., 2009a; Hertrampf et al., 2005; Hertrampf et al., 
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2008b). E2 was provided by Sigma-Aldrich (Deisenhofen, Germany), ER subtype-
selective substances Alpha and Beta were obtained from Bayer Schering Pharma AG, 
Berlin and Gen was obtained from LC Laboratories (Woburn, MA 01801 USA). 
Throughout the treatment period, body weight and food intakes were monitored once a 
week. 
After 10 weeks of treatment, the animals were sacrificed by decapitation after light 
anaesthesia with CO2 inhalation and the blood was collected. The whole abdominal body 
fat (periovarian, perirenal, mesenteric/omental) and the uteri were prepared and the wet 
weights were determined. Periovarian fat pads were immediately fixed in 4% neutrally 
buffered formalin for morphometric analysis. To measure the subcutaneous fat content, a 
piece of 4 cm2 from the back of each animal was dissected and the wet weight was 
determined. The soleus muscles were removed and directly frozen in liquid nitrogen for 
analysis of molecular markers or embedded in TissueTek® (Sakura, Staufen, Germany), 
cooled in isopentane, and frozen in liquid nitrogen for histological analysis. 
 
 
 
 
Fig. 1. Experimental design.  
SHAM = sham operated, OVX =ovariectomized; LF = low fat diet, HF = high fat diet, E2 = treated 
with 17beta-estradiol, Alpha = treated with ER alpha-selective agonist, Beta = treated with ER beta-
selective agonist, Gen = treated with genistein.  
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Table 1. Composition of the diets.  
HF = high fat; LF = low fat. 
 
 
 
 
 
Determination of leptin 
The serum concentration of leptin was measured in duplicate using ELISA kits for rats 
according to the manufacturer’s instruction (ALPCO Diagnostics, Salem, NH 03079, 
USA). 
 
Determination of serum lipids 
Serum was obtained by centrifugation at 4 °C and 3000g and stored at –20 °C. Serum 
levels of triglyceride were analyzed by colorimetry using ABX Pentra reagent (ABX 
Diagnostics Montpellier, France). The determination of TC, HDL and LDL occurred via 
photometry using reagents from DIALAB (Wiener Neudorf, Austria). To measure the 
serum lipids a chemistry analyzer (Roche Hitachi Cobas Mira Plus) was used. 
Concentrations of VLDL were calculated by subtraction of the subunits LDL and HDL from 
TC. 
 
H&E staining and determination of adipocyte areas 
Sections from paraffin embedded periovarian fat tissue were cut at 7 µm thickness. 
Following dewaxing, rehydration, and H&E staining sections were photographed by using 
a light microscope (KS 300, Zeiss, Jena, Germany) and the corresponding Image 
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software 3.0. The areas of adipocytes were measured in captured images using the 
ImageJ program, developed by the National Institutes of Health. 
 
Immunohistochemical staining and determination of soleus muscle fiber areas 
Cross-sections (7 µm) from frozen and Tissue Tek® embedded soleus muscles were fixed 
in ice-cold acetone for 10 minutes. After drying, sections were incubated in 5% BSA/TBS 
for 1h at room temperature to block non-specific binding. Sections were incubated with 
anti-Laminin antibody (L9393, Sigma-Aldrich, Deisenhofen, Germany) at a dilution of 
1:400 in 1% BSA/TBS overnight at 4°C. Then the sections were incubated first with the 
corresponding secondary antibody (E0432, Dako, Glostrup, Denmark) and then with the 
Streptavidin-biotinylated horseradish peroxidase complex (RPN1051V, GE Healthcare, 
Munich, Germany) each 1:400 diluted in TBS for 1h at room temperature. To visualize the 
antigen-antibody complexes 3,3´-Diaminobenzidine-tetrahydrochloride (DAB, Sigma-
Aldrich, Deisenhofen, Germany) was used as substrate. Between the individual incubation 
steps sections were washed several times with TBS. Muscle fiber areas were measured 
with an inverse microscope (Axiovert200, Zeiss, Jena, Germany) and the corresponding 
software AxioVision Rel. 4.6.3. 
 
Real-time RT-PCR experiments 
Total RNA was extracted from frozen soleus muscle tissue using the standard TRIzol® 
method (Life Technologies GmbH, Darmstadt, Germany). RNA was quantified by 
spectrophotometry (NanoDropTM 1000, Thermo Scientific, Wilmington, DE 19810, USA) 
and cDNA was synthesized from 1 µg RNA using a Reverse Transcription System 
(QuantiTect®, Qiagen). Real-time RT-PCR was performed with Taq DNA polymerase 
(Invitrogen, Germany) in the presence of a fluorescent dye (SYBR Green, BioRad) on an 
Mx3005P™ qPCR System (Stratagene). All reactions were run in triplicate in a 50 µl total 
volume. The PCR program was as follows: 95 °C for 3 min for 1 cycle, followed by 35 
cycles of 30 s at 95 °C, 30 s at 58 °C, 30 s at 72 °C, and 1 cycle for 1 min at 72 °C. 
Fluorescence was quantified during the 58 °C annealing step and product formation was 
confirmed by melting curve analysis (58–95 °C). Relative mRNA amounts of target genes 
were calculated after normalization to an endogenous reference gene (Cytochrom c 
Oxidase, subunit 1A) following the ΔΔCT method (Pfaffl, 2001). Specific primer pairs were 
designed based on the genomic sequences available at the UCSC Genome 
Bioinformatics database using the software Primer3 (Rozen and Skaletsky, 2000) and 
confirmed by the sequences in the NCBI database (http://www.ncbi.nlm.nih.gov/). Life 
Technologies GmbH (Darmstadt, Germany) synthesized all the following primers: 1A_fwd 
5’-CGTC ACAGCCCATGCATTCG-3’, 1A_rev 5’-CTGTTCATCCTGTTCCAGCTC-3’, 
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Igf1_fwd 5’-CCGCTGAAGCCTACAAAGTC-3’, Igf1_rev 5’-TGTTTTGCAGGTTGCTC 
AAG-3’, Pax7_fwd 5’-ACTCTGCCTCCTCCATCT CAG-3’, and Pax7_rev 5’-TGTGTA 
GACAGGCTCACGTTTT-3’. 
 
Statistical analysis  
All data are expressed as arithmetic means ± SD. Statistical significance of differences 
was calculated using Kruskal–Wallis one-way analysis of variance with a subsequent 
Mann–Whitney U test. Differences in soleus muscle gene expression were assessed by 
one-way ANOVA followed by Tukey’s HSD post hoc test (SPSS Statistical Analysis 
System, Version 17.0). Statistical significance was established at p<0.05. 
 
 
Results 
 
Diet, energy intake and body weights 
Measurement of uterine wet weight is the most reliable biomarker to determine estrogenic 
activity of administrated compounds (Owens and Ashby, 2002). To ascertain the 
estrogenic response of the experimental treatment and the adequate delivery of 
compounds, the uterine wet weight of all animals was measured. As shown in Fig. 2, OVX 
resulted in a dramatic atrophy of the uterus. The uterine wet weights of those animals 
were 6 to 7-fold lower than the wet weights of the SHAM animals. As expected, treatment 
of OVX rats with E2 and Alpha led to a strong stimulation of uterine wet weight (similar to 
that of SHAM groups), whereas the administration of Beta and Gen revealed no such 
uterotrophic effect. According to earlier studies this result clearly shows that the 
stimulatory effect of E2 on the uterine wet weight is ER alpha mediated (Hertrampf et al., 
2006a; Hertrampf et al., 2008a). 
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Fig. 2. Effects of E2, ER subtype-selective agonists and Gen on uterine wet weights after 10 weeks 
of treatment. 
SHAM = sham-operated, OVX = ovariectomized, E2 = treated with 17beta-estradiol, Alpha = 
treated with ER alpha-selective agonist, Beta = treated with ER beta-selective agonist, Gen = 
treated with Genistein, LF = low fat diet, HF = high fat diet. Data shown are means ± SD. Mean 
values were significantly different for the following comparisons: (a) p≤0.05 vs. OVX LF, (b) p≤0.05 
vs. OVX HF.  
 
 
SHAM and untreated OVX animals fed with the LF diet had a significantly higher food 
intake (1.2 fold) than the respective animal groups on a HF diet (Fig. 3A). However, 
compared to the energy content of the different diets there was no significant difference 
on energy intake among the animal groups (3B). Nevertheless, after 10 weeks of 
treatment and independent from the diets, body weight gain in the SHAM-, E2- and Alpha-
treated groups was significantly lower than in the untreated OVX animals. Treatment of 
OVX rats on HF diet with Beta or Gen did not significantly counteract the body weight gain 
(Fig. 3C).  
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Fig. 3. Effects of E2, ER subtype-selective agonists and Gen on (A) diet intake, (B) energy intake, 
and (C) body weight after 10 weeks of treatment. 
SHAM = sham-operated, OVX = ovariectomized, E2 = treated with 17beta-estradiol, Alpha = 
treated with ER alpha-selective agonist, Beta = treated with ER beta-selective agonist, Gen = 
treated with Genistein, LF = low fat diet, HF = high fat diet. Data shown are means ± SD. Statistical 
significance was established at p≤0.05 and is indicated by lines for the following comparisons: + 
marks a significant difference between OVX and SHAM on LF diet, * marks significant differences 
between OVX HF and other groups on HF diet, # marks significant differences between the two 
different diets. 
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Visceral body fat content, adipocyte size, serum levels of leptin 
Menopause is associated with an increase in body weight, in particular fat mass with a 
simultaneous alteration in fat distribution that seems to be correlated with a massive 
decline of ovarian steroids (Cooke and Naaz, 2004; Heine et al., 2000; Ley et al., 1992). 
In this study, visceral body fat content (periovarian, perirenal, mesenteric omental) and 
adipocyte size (periovarian) were determined. The highest visceral body fat content (Fig. 
4A) as well as the largest adipose cells (Fig. 4B) was observed in untreated OVX HF 
animals. SHAM-, E2- and Alpha-treated animals and interestingly also the Beta-treated 
animals on the same diet revealed significant lower abdominal fat mass as well as smaller 
fat cells. Administration of Gen to OVX HF rats did not influence the abdominal fat mass 
and had only a small effect on adipocyte size. The same OVX induced effect on 
abdominal fat mass and adipocytes was observed in LF diet animal groups, although only 
the adipocyte size was statistically significant. Moreover, comparing the data of SHAM LF 
and HF shows that significant larger adipose cells were measured in the SHAM HF group. 
Furthermore, neither hormone treatment nor diet had a significant effect on subcutaneous 
fat depots (data not shown). Leptin, an adipose tissue derived hormone, is well known as 
a key regulator for energy intake and energy expenditure (Rosen and Spiegelman, 2006). 
The data show that in comparison to the SHAM animals the leptin levels were significantly 
increased in both untreated OVX groups (Fig. 4C). The combinatory effect of ovariectomy 
and HF diet seems to have an additive effect and led to even higher leptin values. Serum 
leptin levels of OVX rats were significantly lowered following the application of E2, Alpha 
and Beta but not by administration of Gen.  
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Fig. 4. Effects of E2, ER subtype-selective agonists and Gen on (A) visceral body fat content, (B) 
adipocyte size, and (C) serum leptin after 10 weeks of treatment. 
SHAM = sham-operated, OVX = ovariectomized, E2 = treated with 17beta-estradiol, Alpha = 
treated with ER alpha-selective agonist, Beta = treated with ER beta-selective agonist, Gen = 
treated with Genistein, LF = low fat diet, HF = high fat diet. Data shown are means ± SD. Statistical 
significance was established at p≤0.05 and is indicated by lines for the following comparisons: + 
marks a significant difference between OVX and SHAM on LF diet, * marks significant differences 
between OVX HF and other groups on HF diet, # marks significant differences between the two 
different diets. 
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Serum levels of lipids 
The serum lipid levels after 10 weeks of treatment are shown in Fig. 5. Compared to 
SHAM animals, OVX resulted in significantly higher serum levels of TC and their subunits 
HDL, LDL, and VLDL. The LF diet seems to increase this effect, although this effect was 
statistically significant only for the LDL level. Concentrations of TC and VLDL were 
reduced by treatment with E2 and Alpha. In the same animal groups, a mild reduction of 
LDL was observed, while the HDL concentration remained unchanged. The application of 
Beta or Gen showed no significant impact on TC or their subunits. Serum triglyceride 
levels were not influenced by treatment or different diet (data not shown). 
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Fig. 5. Effects of E2, ER subtype-selective agonists and Gen on serum lipids after 10 weeks of 
treatment. 
SHAM = sham-operated, OVX = ovariectomized, E2 = treated with 17beta-estradiol, Alpha = 
treated with ER alpha-selective agonist, Beta = treated with ER beta-selective agonist, Gen = 
treated with Genistein, LF = low fat diet, HF = high fat diet. Data shown are means ± SD. Statistical 
significance was established at p≤0.05 and is indicated by lines for the following comparisons: + 
marks a significant difference between OVX and SHAM on LF diet, * marks significant differences 
between OVX HF and other groups on HF diet, # marks significant differences between the two 
different diets. 
 
 
 
mRNA expression of Igf1 and Pax7 in the soleus muscle 
Our results regarding body weight and visceral body fat content clearly indicate a negative 
correlation in the Beta-treated animals. These animals have a relative high body weight 
(similar to untreated OVX HF animals), but a relative low visceral body fat content (similar 
to E2- and Alpha-treated OVX HF animals). Based on the observation, it can be 
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hypothesized that Beta-treated animals have a higher fat-free body mass. Therefore, 
anabolic effects of the Beta selective agonist on the soleus muscle were measured. 
mRNA expression of Igf1 as an indicator for anabolic activity (Barton-Davis et al., 1998; 
Barton-Davis et al., 1999; Mavalli et al., 2010; Philippou et al., 2007; Weber, 2002) and of 
Pax7 as a marker for the specification/expansion of the satellite cell population (Charge 
and Rudnicki, 2004) were measured. Satellite cells, the so called myogenic stem cells, are 
required for post-natal growth, repair and maintenance of skeletal muscles (Chen and 
Goldhamer, 2003). OVX rats on the HF diet showed significantly higher mRNA level of 
Igf1 in the soleus muscle than SHAM animals. Application of E2, Beta, and Gen but not 
Alpha antagonized this OVX effect. Furthermore compared to OVX animals on the LF diet, 
the HF diet in OVX rats led to even higher Igf1 expression levels (Fig. 6A). Independent of 
the diet, ovariectomy resulted in a significant down-regulation of Pax7 gene expression 
compared with SHAM animals. Treatment with E2 and Beta completely antagonized the 
OVX induced effect, whereas the application of Alpha and Gen revealed only a tendency 
(Fig. 6B). 
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Fig. 6. Effects of E2, ER subtype-selective agonists and Gen on mRNA expression of (A) Igf1 and 
(B) Pax7 in the soleus muscle after 10 weeks of treatment. 
SHAM = sham-operated, OVX = ovariectomized, E2 = treated with 17beta-estradiol, Alpha = 
treated with ER alpha-selective agonist, Beta = treated with ER beta-selective agonist, Gen = 
treated with Genistein, LF = low fat diet, HF = high fat diet. Data shown are means ± SD. Statistical 
significance was established at p≤0.05 and is indicated by lines for the following comparisons: + 
marks a significant difference between OVX and SHAM on LF diet, * marks significant differences 
between OVX HF and other groups on HF diet, # marks significant differences between the two 
different diets. 
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Cross-sectional areas of soleus muscle fibers 
Gene expression patterns of Pax7 and Igf1 indicate an anabolic activity of Beta in the 
soleus muscle. To confirm further these results, the soleus muscle fiber cross-sectional 
areas in histological sections were measured. Treatment of OVX HF rats with E2 and Beta 
led to significantly larger muscle fibers compared with untreated OVX HF animals, 
whereby the largest muscle fibers were measured in the Beta-treated animals (Fig. 7). 
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Fig. 7. Effects of E2 and Beta on soleus muscle fiber sizes after 10 weeks of treatment. 
OVX = ovariectomized, E2 = treated with 17beta-estradiol, Beta = treated with ER beta-selective 
agonist, HF = high fat diet. Data shown are means ± SD. * marks significant differences as 
indicated by lines vs. OVX HF. Statistical significance was established at p≤0.05. 
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Discussion 
 
The goal of the study was to obtain more detailed insights into the action of E2 on energy 
intake, body weight, lipid metabolism and fat to muscle mass ratio in a rat model of 
nutrition-induced obesity. Special emphasis was given to the effects of synthetic ER 
subtype-selective agonists Alpha and Beta and the phytoestrogen Gen.  
In line with already published data (Hertrampf et al., 2007; Hertrampf et al., 2008b; 
Hillisch et al., 2004) it is clearly visible that uterine growth response is ER alpha mediated 
(Fig. 2). Moreover, the response of the uterus to administration of ER ligands is a clear 
indication for the adequate delivery of the estrogenic compounds by osmotic mini pumps 
or enriched food. 
A major focus of this study was to investigate effects of the different ER agonists on 
the development of body weight and fat mass. Previous studies demonstrated that E2 
supplementation in OVX animals significantly decreases body weight via ER alpha 
mediated mechanisms (Hertrampf et al., 2007; Hertrampf et al., 2008b). The data 
obtained from the present study confirm this result and suggest that the HF diet given to 
OVX animals has an additive, although non-significant stimulatory effect on body weight 
gain compared to OVX animals on LF diet (Fig 3C). An important finding of the present 
study is the observation that the modulation of weight gain by the different ER ligands is 
not caused by a modulation of energy intake. In fact, the influence of E2 on food intake 
has been discussed controversially. Meli and colleagues reported a significantly lower 
food intake in E2 supplemented OVX rats and SHAM animals compared to untreated OVX 
rats (Meli et al., 2004). Naaz et al. assumed that the anorectic action of E2 is ER alpha 
mediated (Naaz et al., 2002). In contrast, another group, using OVX female Wistar rats 
postulated that ER beta in the central nervous system is involved in the inhibitory effect of 
estrogens on food intake (Liang et al., 2002). In the present study, only the groups fed 
with the LF diet showed significantly higher food intake following 10 weeks of treatment. 
This effect could be due to the lower content of metabolizable energy in the diet, since no 
significant differences in terms of energy intake between all animal groups was measured 
(Fig 3A,B). This finding is in line with previous results of our group and others (Heine et 
al., 2000; Zoth et al., 2010) and demonstrates that differences in weight gain are caused 
by alterations in the metabolic activity by the estrogenic compounds and not by a different 
intake of energy. 
Over the last decades, numerous studies have shown that adipose tissue plays a 
major role in the regulation of energy balance (Barsh and Schwartz, 2002; Rosen and 
Spiegelman, 2006). Obesity, caused by an excessive enrichment of adipose tissue, 
especially intra-abdominal fat, constitutes a massive risk for metabolic abnormalities 
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(Chan and Woo, 2010; Mokdad et al., 2003; Swinburn et al., 2004; Wasan and Looije, 
2005). Men tend to have more visceral fat enrichment whereas perimenopausal women 
accumulate more fat subcutaneously. After menopause, fat distribution in women 
becomes resembles that in men due to a decline of endogenous estrogens, clearly 
indicating that estrogens are involved in adipose tissue biology (Ley et al., 1992; Toth et 
al., 2000b). Previous reports indicate a direct anti-lipogenic and pro-lipolytic action of 
estrogens in adipose tissue (D'Eon et al., 2005; Rogers et al., 2009), but the underlying 
molecular mechanisms and whether these actions are mediated via ER alpha and/or ER 
beta have been not fully elucidated so far. For example, a study undertaken by Heine and 
colleagues revealed an increase of adipose tissue in male and female αERKO mice 
(Heine et al., 2000). Another experiment, using the stable ER alpha transfected 3T3-L1 
pre-/adipocyte cell line showed reduced lipoprotein lipase mRNA and decreased 
triglyceride accumulation (Homma et al., 2000). In contrast, a recently published research 
paper suggests an anti-lipogenic action of ER beta in adipose tissue mediated via a 
negative cross talk of ER beta with PPAR gamma (Foryst-Ludwig et al., 2008). The 
present study using highly subtype-selective ER agonists clearly demonstrate that 
activation of the ER alpha and the ER beta results in a reduction of adipose tissue mass. 
The visceral body fat mass was significantly lower and the adipocyte size was significantly 
smaller in E2-, Alpha-, and Beta-treated animals in comparison to untreated OVX HF 
animals (Fig. 4A,B). This result suggests a beneficial role of E2 preventing metabolic 
abnormalities because of the existing link between large increases of adipose tissue and 
impaired glucose tolerance and insulin sensitivity (Chan and Woo, 2010; Heine et al., 
2000). 
A further indication that body fat mass was affected by E2, Alpha, and Beta comes 
from data concerning Leptin modulation. Leptin, a hormone almost exclusively secreted 
by adipocytes, circulates in the blood directly in proportion to the amount of adipose tissue 
(Friedman, 2002; Maffei et al., 1995). Thus, leptin serves as an indicator of body energy 
storage. The hormone acts on specific regions of the brain (primarily the hypothalamus) to 
reduce food intake and to enhance energy expenditure by modulating the expression of 
several neuropeptides (Barsh and Schwartz, 2002; Rosen and Spiegelman, 2006; 
Schwartz, 2001; Schwartz, 2006; Schwartz et al., 1996). Additionally, various reports have 
described anti-hyperglycaemic actions of leptin through improvement of insulin sensitivity 
in muscles and liver as well as the ability of leptin to prevent the accumulation of lipids in 
non-adipose tissues (Kamohara et al., 1997; Minokoshi et al., 2002). Leptin data 
presented in this study confirm the well-documented correlation between body fat mass 
and circulating leptin levels in the blood. The E2-, Alpha- and Beta-treated animals as well 
as the SHAM-treated animals, which showed significantly lower visceral fat mass than the 
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untreated OVX HF animals also exhibited significantly lower leptin levels (Fig 4C). 
Different studies have shown that obesity is accompanied by high serum leptin levels, 
which is generally attributed to central leptin insensitivity (Furuhata et al., 2000; Morrison, 
2008; Morton et al., 2006). 
In the study presented here, the Beta-treated animal group shows a discrepancy 
between the body weights on the one hand and the visceral body fat content and the 
serum leptin level on the other. Similar to the E2- and Alpha-treated groups the Beta-
treated animals had relative low visceral body fat and serum leptin, but a relative high 
body weight comparable to untreated OVX and Gen-treated animals (Fig. 3C, 4). An 
important role of the ER beta for skeletal muscle growth and regeneration was established 
in our laboratory using subtype selective agonists or βERKO mice in a model of toxin 
induced skeletal muscle injury. ER beta-selective agonist accelerated the regeneration of 
damaged skeletal muscles in female rats and revealed anabolic potency in a classical 
Hershberger assay using healthy male Wistar rats (Velders, 2011). Based on these 
observations, it can be speculated that treatment with the selective ER beta agonist may 
also increase the skeletal muscle mass in female Wistar rats in a model of nutrition-
induced obesity. The mRNA data of Igf1 and Pax7 in the soleus muscle, presented in this 
study, support this hypothesis, since both genes were significantly modulated through the 
substitution of OVX HF animals with E2, Beta, and partly by Gen but not by Alpha 
compared to untreated OVX HF animals (Fig. 6). Pax7, a paired-box transcription factor, 
is specifically expressed in satellite cells and is essential for satellite cell function. Muscle 
satellite cells are myogenic progenitors in adult skeletal muscle and are responsible for 
growth, repair and maintenance of skeletal muscle (Chen and Goldhamer, 2003; Hawke 
and Garry, 2001; Kuang et al., 2006). Igf1 as a potent anabolic marker is involved in the 
regulation of muscle growth via activation of satellite cells and stimulation of protein 
synthesis (Barton-Davis et al., 1999; Mavalli et al., 2010; Philippou et al., 2007; Svensson 
et al., 2010). Recent studies have shown that E2 substitution of gonadectomized rodents 
enhanced skeletal muscle regeneration and maintenance by increasing the number of 
total, activated, and proliferating satellite cells and by affecting the Igf1 signalling cascade 
(Enns and Tiidus, 2008; Svensson et al., 2010; Tiidus et al., 2005). The results obtained in 
this study suggest that signaling through ER beta is responsible for these effects and 
seems to be the reason for the larger soleus muscle fiber sizes in Beta- and E2-treated 
rats compared with untreated OVX animals (Fig. 7). This findings strongly indicate that 
skeletal muscle mass, at least in the soleus muscle, is enhanced in Beta- and E2-treated 
groups compared to untreated OVX animals. The slow-twitch fiber type soleus, rich in 
mitochondria, and located in the back part of the lower leg generates energy (ATP) 
predominantly by means of oxidative metabolism, whereby besides glucose mainly fatty 
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acids serve as substrates (Baker et al., 2010; Delp and Duan, 1996; Janovska et al., 
2010; Scott et al., 2001). Previous studies have shown that in oxidative muscles the 
insulin binding capacity, the kinase activity of the insulin receptor, the content of glucose 
transporter 4, and the insulin-stimulated glucose uptake is higher than in glycolytic 
muscles (Bonen and Tan, 1981; James et al., 1986; Kern et al., 1990). Against this 
background, the present results suggest that the ER beta improves energy homeostasis in 
the soleus muscle through enhanced utilization of glucose and lipids. 
One important risk factor for the development of cardiovascular diseases is an 
unfavourable change in the lipoprotein profile. Hypercholesteremia coupled with low HDL 
and high LDL and VLDL levels are well documented. Obesity, type 2 diabetes mellitus, 
insulin resistance, but also the loss of ovarian function after the onset of post-menopause 
is associated with this kind of dyslipidemia (Baxter et al., 2003; Bierman, 1992; Chan and 
Woo, 2010; Kushwaha et al., 1990; Sbarouni et al., 1998; Schaefer, 2002; van Beek et al., 
1999). Therefore, serum lipid profiles were determined. Figure 5 shows that ovariectomy 
raises the concentrations of TC, HDL, LDL, and VLDL independent from different diets 
compared to SHAM animals. Treatment with E2 and ER alpha selective agonist led to a 
significant reduction of TC and VLDL in comparison to OVX HF rats. The same animal 
groups also showed a slight decrease of LDL, whereas HDL levels were not altered. Thus, 
the LDL/HDL ratio as well as the (VLDL+LDL)/HDL ratio is more favourable concerning 
the development of cardiovascular diseases in the SHAM-, E2- and Alpha-treated groups 
compared to untreated OVX animals. This beneficial impact of E2 on blood lipids is in line 
with other studies and explains the relative cardiovascular protection of premenopausal 
women in comparison to women after menopause and men (Dubey et al., 2005; Ling et 
al., 2006). This study demonstrates that the positive effect of E2 is mediated via ER alpha 
and agrees with the observation that the liver, as the most important tissue in the 
modulation of blood lipid composition, primarily expresses the ER alpha (Matthews and 
Gustafsson, 2003; Taylor and Al-Azzawi, 2000). 
Taken together, the results clearly show that E2, Alpha and Beta significantly 
modulate various metabolic parameters investigated in this study. In contrast, the 
phytoestrogen Gen, orally administrated, only showed an effect on Igf1 and Pax7 mRNA 
expression in the soleus muscle (Fig. 6). It has been reported that the isoflavone Gen 
decreases food intake, body weight and adipose tissue mass (Kim et al., 2006; Lee et al., 
2006; Michael McClain et al., 2006; Naaz et al., 2003; Penza et al., 2006; Yang et al., 
2006). However, the administrated doses of Gen (subcutaneous and/or dietary) in these 
animal experiments exceeded the dose used in our study. The rats in our study received 
Gen in the range from 60 to 25 mg/kg b. wt per day (changes in intake must be attributed 
to an increase of body weight with a decrease of food intake during the whole 
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experimental period, observed among all animal groups). Such high dosages can only be 
obtained with dietary supplements but not with dietary uptake in humans (Reagan-Shaw 
et al., 2008). A human equivalent dose can be reached by a daily dose which is two to 
four times higher than the maximum dose commonly used for postmenopausal treatment 
(Andres and Lampen, 2012; Hooper et al., 2010; Mahady, 2005; Messina and Wood, 
2008; Steinberg et al., 2011; Wei et al., 2012). The data indicate that such a dose has no 
influence on energy intake, body weight, visceral fat mass or adipocyte size (Fig. 3 and 
4A,B). This interpretation is in agreement with other studies using similar Gen doses (Kim 
et al., 2006; Naaz et al., 2003; Penza et al., 2006). However, Gen-treated animals display 
a similar mRNA modulation of Igf1 and Pax7 as compared with Beta and E2 treatment 
(Fig. 6). Therefore, based on the knowledge that Gen has a pronounced binding affinity to 
ER beta (Kuiper et al., 1997), its role in skeletal muscle homeostasis needs further 
investigations. There are also controversial reports about the effects of Gen on serum lipid 
levels (Kirk et al., 1998). In the study presented here, Gen treatment did not affect the 
serum lipid profile (Fig. 5). 
In general, the HF diet, fed to animals in this study, was used to induce obesity. This 
approach made is possible to examine the impact of hormonal treatment on obese OVX 
rats. The LF diet used in the study served as control and was only fed to SHAM and 
untreated OVX animals. The results shows that the HF diet led to higher body weight gain, 
visceral fat mass, adipocyte sizes, as well as serum levels of leptin in SHAM and 
untreated OVX animals compared to the same groups fed with the LF diet. However, the 
differences were statistically not significant (except adipocyte sizes in SHAM animals). 
Interestingly, serum levels of TC and LDL in OVX animals on LF diet were higher than in 
OVX animals receiving the HF diet (statistifically significant only on LDL results). 
Therefore, after an experimental period of 10 weeks the loss of ovarian function resulted 
in effects that were more adverse regarding body weight and visceral fat mass than the 
fat-enriched diet. 
 
 
Conclusion 
 
In summary, our results show that E2, the ER selective agonists and Gen had no 
significant effect on energy uptake. The lower body weight gain observed in E2-treated as 
compared with untreated OVX rats can be attributed to ER alpha mediated effects. 
Visceral fat content, adipocyte size as well as serum leptin concentration were 
significantly reduced by substitution of OVX rats with E2, ER alpha and ER beta agonists. 
These results can be taken as a strong indication that the positive effects of E2 on 
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parameters involved in regulation of fat metabolisms are mediated via both the ER alpha 
and the ER beta. Serum lipid levels reveal that the E2 induced decrease of TC and VLDL 
is predominantly mediated via the ER alpha. The administration of Gen (when provided in 
the form and dose used in this study) to OVX HF animals has no beneficial influence on 
the investigated parameters in adipose tissue and blood. The soleus muscle mRNA 
expression of Igf1 and Pax7, genes involved in growth, repair and maintenance of skeletal 
muscle, were affected by treatment with E2, Beta, and partly by administration of Gen. 
Soleus muscle fiber cross-sectional areas were significantly larger in E2- and Beta-treated 
animals compared to untreated OVX animals. Thus, the ER beta seems to have the 
potency to increase the skeletal muscle mass which may result in an improved glucose 
uptake, insulin sensitivity and an enhanced utilization of glucose and lipids. Therefore, our 
data suggest that the ER beta has a specific role in the regulation of skeletal muscle 
homeostasis whereas ER alpha may dominate in regulating effects in adipose tissue. To 
acquire deeper knowledge about the underlying molecular mechanisms of estrogenic 
effects on metabolic pathways, future mechanistic studies in adipose tissue but also in the 
liver, pancreatic tissue and skeletal muscle are warranted. 
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Abstract 
 
The molecular mechanisms underlying the effects of selective ER subtype activation on 
lipogenesis, adipogenesis, lipid utilization and storage as well as glucose metabolism are 
currently largely unknown and were analyzed in female OVX Wistar rats on a high-fat diet. 
Rats received 17beta-estradiol (E2), ER subtype-selective agonists (Alpha and Beta), and 
genistein (Gen) for 10 weeks. In adipose tissue, E2, Alpha, and Beta significantly 
decreased lipogenic (SREBP-1c, FAS) and adipogenic genes (LPL, PPAR gamma). In 
liver and skeletal muscle of E2-, Alpha-, Beta-, and Gen-treated animals, lipogenesis and 
triglyceride accumulation were significantly reduced. Increased hepatic and muscular 
PPAR gamma mRNA expression was observed in untreated, Beta- and Gen-treated 
animals, which correlates with increased hepatic glucose uptake. However, only untreated 
animals showed impaired insulin sensitivity compared to all other groups. Therefore, 
PPAR gamma up-regulation in untreated animals suggests a compensatory mechanism, 
probably due to increased triglyceride accumulation in non-adipose tissues. Beta- and 
Gen-treated animals may benefit from the anabolic potency of ER beta that ameliorates 
lipid and glucose utilization in muscle. Activation of either ER subtype reduces fat 
enrichment and improves systemic insulin sensitivity. Depending on the investigated 
tissue, different molecular pathways seem to be involved.  
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Introduction  
 
Obesity, defined as excessive fat accumulation, is one of the major public health 
challenges of our time. Between 1980 and 2008, its prevalence has nearly doubled 
worldwide, with tripling rates being observed in many European countries. In 2008, 1.5 
billion adults were overweight (BMI greater than 25 kg/m2) worldwide. Of those affected 
more than 200 million men and around 300 million women can be classified as obese 
(BMI greater than 30 kg/m2) (WHO, 2012). In addition, the number of overweight children 
increased steadily since 1990. In 2010, nearly 43 million children under five were 
overweight worldwide (WHO, 2010). These numbers are expected to continue to rise, 
particularly among children. Excessive body weight is now recognized to drastically 
increase the risk of developing a number of chronic diseases. These include 
cardiovascular diseases (mainly heart disease and stroke), T2DM, musculoskeletal 
disorders, dyslipidemia, hypertension, and certain forms of cancer. Consequently, obesity 
and its co-morbidities are responsible for constantly rising health costs and premature 
death. Obesity is most likely caused by combination of genetic, behavioural, and 
environmental factors (Chen et al., 2009; Comuzzie et al., 2001; Goulart et al., 2009). 
However, the most common reason for the epidemic growth of obesity rates over the last 
several decades is thought to be a chronic imbalance of energy homeostasis due to 
increased caloric intake combined with a sedentary lifestyle (Chen et al., 2009; Low et al., 
2009; Newbold et al., 2009; Wasan and Looije, 2005). 
Estrogens are well known to regulate energy homeostasis through the modulation of 
glucose and fat metabolism (Ropero et al., 2008). For example, systemic loss of 
endogenous estrogens in women following menopause is associated with body weight 
gain combined with the development of visceral obesity, insulin resistance and T2DM 
(Curtis and Wilson, 2005; Ley et al., 1992; Louet et al., 2004; Toth et al., 2000a). 
Numerous clinical studies investigating the effect of HRT on postmenopausal women 
have shown a decrease of central obesity, lower incidence of T2DM, increased sensitivity 
towards glucose and insulin, and an improvement in lipid metabolism (Andersson et al., 
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1997; Curtis and Wilson, 2005; Kanaya et al., 2003; Pentti et al., 2009; Samaras et al., 
1999; Santen et al., 2010). Similar observations have been made in several animal 
experiments. Ovariectomy in rodents leads to body weight gain and the development of 
obesity, whereas E2 supplementation antagonized these effects (Hertrampf et al., 2006a; 
Hertrampf et al., 2008b; Naaz et al., 2002; Zoth et al., 2010).  
Estrogens exerts their physiological effects via two ER subtypes, ER alpha and ER 
beta. How these subtypes, especially ER alpha, affect metabolism pathways has been 
intensively investigated in the last decade. The suppressive role of ER alpha on body 
weight gain has been convincingly shown in a number of studies (Bryzgalova et al., 2006; 
Heine et al., 2000; Hertrampf et al., 2007; Hertrampf et al., 2008a; Hertrampf et al., 
2008b). The influence of ER alpha and ER beta on energy intake is still a matter of 
debate. Both the activation of ER alpha (Naaz et al., 2002) and the activation of ER beta 
(Liang et al., 2002) have been described to reduce food intake.  
Regarding glucose metabolism, the loss of ER alpha was shown to impair systemic 
glucose tolerance and insulin sensitivity in mice (Barros et al., 2009; Barros et al., 2006; 
Bryzgalova et al., 2006; Heine et al., 2000). By contrast, in ER beta-deficient mice glucose 
tolerance was similar to their wild type counterparts (Barros et al., 2009; Barros et al., 
2006; Bryzgalova et al., 2006). Conversely, the activation of ER alpha using the ER alpha 
selective agonist PPT (propyl pyrazole triol) improved glucose tolerance and insulin 
sensitivity in mice compared to vehicle-treated animals (Lundholm et al., 2008). The role 
of ER beta was not investigated in this study. In skeletal muscle and white adipose tissue, 
ER alpha deficiency was shown to reduce GLUT4 expression when compared to wild 
types, while the loss of ER beta revealed the opposite effect, suggesting a pro-diabetic 
effect of ER beta (Barros et al., 2009; Barros et al., 2006). Furthermore, ER alpha-
deficient mice displayed also hepatic insulin resistance compared to wild types that was 
associated with increased expression of lipogenic genes in liver (Bryzgalova et al., 2006). 
The role of ER beta in hepatic lipogenesis was not investigated in this study. Moreover, in 
comparison to wild type mice, the loss of ER alpha in mice of both sexes was described to 
increase white adipose tissue mass (Heine et al., 2000). Another study using the stable 
ER alpha-transfected 3T3-L1 pre-/adipocyte cell line displayed reduced lipoprotein lipase 
mRNA and decreased TG accumulation (Homma et al., 2000). These results suggest an 
important role of ER alpha in adipose tissue biology, but again, the impact of ER beta was 
not investigated in these two studies. ER beta has been shown to reduce PPAR gamma 
expression in adipocytes (Foryst-Ludwig et al., 2008). Overexpression of ER beta, but not 
ER alpha, resulted in a decreased PPAR gamma transcriptional activity and inhibited 
adipocyte differentiation in 3T3-L1 preadipocytes. A subsequent in vivo experiment 
revealed that ER beta deficiency increased PPAR gamma activity in adipose tissue and 
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led to increased body weight and fat mass in the presence of improved insulin sensitivity 
compared to wild type mice (Foryst-Ludwig et al., 2008). Taken together, activation of ER 
alpha has been shown to improve glucose and lipid metabolism, while the role of ER beta 
on energy homeostasis needs clarification. 
Recently, the impact of the ER subtype-selective agonists, 16alpha-LE2 (Alpha) and 
8beta-VE2 (Beta), and the phytoestrogen genistein (Gen) on energy homeostasis in a rat 
model of nutrition-induced obesity was investigated. The results clearly demonstrated that 
neither Alpha nor Beta affected food uptake. Treatment with Alpha reduced the body 
weight gain, visceral fat mass, adipocyte size, and serum levels of leptin and lipids 
compared to untreated rats. Beta treatment did not decrease blood lipids or body weight 
but reduced fat mass and adipocyte size. In addition, selective activation of ER beta 
increased skeletal muscle mass (Weigt et al., 2011) which could explain the higher body 
weight of these animals. By contrast, application of Gen, orally administered in a daily 
dose, which was two to four times higher than an equivalent dose commonly used for 
postmenopausal treatment (Andres and Lampen, 2012; Hooper et al., 2010; Messina and 
Wood, 2008; Steinberg et al., 2011; Wei et al., 2012), had no significant influence on the 
investigated parameters in adipose tissue or blood. However, it may affect skeletal muscle 
homeostasis similar to the ER beta subtype-selective agonist (Table 2) (Weigt et al., 
2012). 
The aim of the current study was to further investigate the underlying molecular 
mechanisms behind the effects of ER subtype-selective agonists and Gen on energy 
homeostasis. Therefore, the impact of Alpha-, Beta- and Gen-treatment on the expression 
of genes involved in the regulation of glucose and fatty acid metabolism in adipose tissue 
(SREBP-1c, FAS, LPL, and PPAR gamma), liver (SREBP-1c, FAS, PPAR alpha, and 
PPAR gamma), and soleus muscle (SREBP-1c, FAS, PPAR alpha, PPAR gamma, and 
PPAR delta) was investigated. TG content in muscle and liver was determined. 
Furthermore, to investigate glucose tolerance in the animals, the systemic insulin level 
and the hepatic glucose uptake by using isotope-ratio mass spectrometry (IRMS) were 
measured. 
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Materials and methods 
 
Animals 
Juvenile female Wistar rats (6-weeks old, 120–150g) were obtained from Janvier (Janvier, 
Le Genest St Isle, France) and kept at constant room temperature (20 °C ± 1), relative 
humidity (50–80%) and illumination (12 h light/dark cycles). The animals were housed 3–4 
in each cage, with food (SSniff GmbH, Soest, Germany) and water provided ad libitum. All 
animal procedures were approved by the Committee on Animal Care and compliant with 
accepted veterinary medical practice.  
 
Animal diet 
Two different diets were used. First, a phytoestrogen-free LF diet (ssniff® EF D12450B* 
(I) mod. LS* containing a metabolizable energy of 15.0 MJ/kg) was used that contains soy 
oil as the sole source of fat (2.5%). Thus, this diet is rich in unsaturated fatty acids 
(approx. 25 % C18:1 n9, > 50 % 18:2 n6) and served as control diet. As a second diet, a 
phytoestrogen-free HF diet (ssniff® EF R/M acc. D12451 (I) mod.* containing a 
metabolizable energy of 19.2 MJ/kg) was used. The main source of fat (20.5 %) in this 
diet originates from animals (lard) and only 5 % from soy oil (to cover the needs of 
essential fatty acids), resulting in a high level of saturated fatty acids. The HF diet was 
designed to induce obesity and secondary diseases. The protein source in both diets was 
casein (detailed composition of diets was described before (Weigt et al., 2012)). A portion 
of the HF diet was enriched with genistein (700 mg/kg diet), enabling an oral route of 
exposure. Gen was obtained from LC Laboratories (Woburn, MA 01801 USA). Ssniff 
Spezialdiäten GmbH, Soest, Germany, provided the food enrichment with Gen. 
 
Animal treatment  
Prior to experimental exposure procedures, all animals were ovariectomized (OVX) or 
SHAM operated (SHAM) via the dorsal route. Following 2 weeks of regeneration and 
endogenous hormonal decline the animals were randomly allocated to different treatment 
and diet groups (n=7, animal grouping was described before (Weigt et al., 2012)). All 
SHAM animals and a subset of OVX animals received either the LF diet or the HF diet. 
The remaining OVX animals were fed with the HF diet and treated with E2, Alpha (the ER 
alpha-selective agonist 16alpha-LE2 (3,17-dihydroxy-19-nor-17alpha-pregna-1,3,5(10)-
triene-21,16alpha-lactone)), Beta (the ER beta-selective agonist 8beta-VE2 (8-vinylestra-
1,3,5(10)-triene-3,17beta-diol)) or Gen. E2 (4 µg/kg b.wt per day), Alpha (10 µg/kg b.wt 
per day), and Beta (100 µg/kg b.wt per day) were applied via ALZET® osmotic mini 
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pumps, whereby the substances were dissolved in dimethylsulfoxide and water according 
to the manufacturer’s instructions for filling. Gen was administered via Gen-enriched food 
(about 42 mg/kg b.wt per day. The treatment doses of the respective substances were 
chosen based on previous experiments (Diel et al., 2004; Hegele-Hartung et al., 2004; 
Hertrampf et al., 2009a; Hertrampf et al., 2005; Hertrampf et al., 2008b). E2 was provided 
by Sigma-Aldrich (Deisenhofen, Germany) and the ER subtype-selective substances 
Alpha and Beta were obtained from Bayer Schering Pharma AG, Berlin. These two 
steroidal and highly subtype-selective agonists Alpha and Beta were synthesized to 
specifically fit differences in the three-dimensional structure of the ligand-binding domain 
of the two ERs. In vitro studies using radio-ligand competition assays showed for 16alpha-
VE2 a 70-fold higher affinity to ER alpha compared to ER beta (tested for rERs and 
hERs). 8beta-VE2 binds preferentially to ER beta (93-fold preference for rER beta and 
180-fold preference for hER beta). The estrogenic potency was also documented in 
transactivation experiments, where 16alpha-LE2 exhibited a 250-fold ER alpha selectivity 
and 8beta-VE2 183-fold ER beta selectivity. Subsequent animal experiments in female 
Wistar rats confirmed the selective stimulation of either ER alpha or ER beta. More 
detailed information about the structure-based design, the synthesis strategy, and the 
characterization of both ligands (in vitro and in vivo) can be found elsewhere (Hillisch et 
al., 2004). Selectivity of this two ER subtype agonists was also shown by the analysis of 
the uterine wet weights in our uterotrophic assay (Weigt et al., 2012). According to earlier 
studies, only the ER alpha agonist mediated uterine growth, while the ER beta agonist did 
not (Hertrampf et al., 2007; Hertrampf et al., 2008a). Throughout the treatment period, 
body weight and food intakes were monitored once a week. On the day before section, 
the food was removed at 8 p.m. for an overnight fast. 
After 10 weeks of treatment, the animals were sacrificed by decapitation after light 
anaesthesia with CO2 inhalation and blood was collected. Periovarian fat pads, liver, and 
soleus muscle were collected and directly frozen in liquid nitrogen for analysis of 
molecular markers. Tissue wet weights, energy intake, histological analysis of the soleus 
muscle, as well as serum levels of leptin and lipids were investigated and published 
before (Weigt et al., 2012). 
 
Real-time RT-PCR experiments 
Total RNA was extracted from frozen tissues (liver, periovarian fat, soleus muscle) using 
the standard TRIzol® method (Life Technologies GmbH, Darmstadt, Germany). RNA was 
quantified by spectrophotometry (NanoDropTM 1000, Thermo Scientific, Wilmington, DE 
19810, USA) and cDNA was synthesized from 1 µg RNA using a Reverse Transcription 
System (QuantiTect®, Qiagen). Real-time RT-PCR was performed with Taq DNA 
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polymerase (Life Technologies GmbH, Darmstadt, Germany) in the presence of a 
fluorescent dye (SYBR Green, BioRad) on an Mx3005P™ qPCR System (Stratagene). All 
reactions were run in triplicate in a total volume of 50 µl. The PCR program was as 
follows: 95 °C for 3 min for 1 cycle, followed by 35 cycles of 30 s at 95 °C, 30 s at 58 °C 
(60°C for amplification of ER alpha and ER beta mRNA), 30 s at 72 °C, and 1 cycle at 72 
°C for 1 min. Fluorescence was quantified during the annealing step and product 
formation was confirmed by melting curve analysis. Relative mRNA amounts of target 
genes were calculated after normalization to an endogenous reference gene (cytochrom c 
oxidase, subunit 1A) following the delta delta CT method (Pfaffl, 2001) with exception of 
ER alpha and ER beta mRNA amplification. Here, the PCR products were separated on 
2 % agarose gels and visualized by ethidium bromide staining under UV illumination. 
Specific primer pairs were published before (Höfer et al., 2009; Möller et al., 2009) or 
designed based on the genomic sequences available at the UCSC Genome 
Bioinformatics database using the software Primer3 (Rozen and Skaletsky, 2000) and 
confirmed by the sequences in the NCBI database (http://www.ncbi.nlm.nih.gov). The 
primers were synthesized by Life technologies GmBH (Darmstadt, Germany) and are 
depicted in Table 3. The metabolic role of the analyzed genes involved in lipid and 
glucose metabolism is described in the supplementary material Table 4. 
 
Table 3. Primers used in Real-time RT-PCR experiments. 
 
Gene Direction Primer sequenz (5' - 3') published in 
    
1A fwd CGTCACAGCCCATGCATTCG Höfer et al., 2009 
 rev CTGTTCATCCTGTTCCAGCTC  
SREBP-1c fwd GTACCTGCGGGACAGCTTAG  
 rev CAGGTCATGTTGGAAACCAC  
FAS fwd GGCTAGAGACCTTGGCACTG  
 rev TAGCCCTCTGCTCTGGTCAC  
LPL fwd TGCCATGACAAGTCTCTGAAG  
 rev TGCTATCGGCCATTAGGTTC  
PPAR alpha fwd GGCTGCTATAATTTGCTGTGG  
 rev TTCTTGATGACCTGCACGAG  
PPAR gamma fwd GCCCTTTGGTGACTTTATGG  
 rev CATCTTCTGGAGCACCTTGG  
PPAR delta fwd TCATTGAGCCCAAGTTCGAG  
 rev GGAAGAGGTACTGGCTGTCG  
ER alpha fwd GGAAGCACAAGCGTCAGAGAGAT Möller et al., 2009 
 rev AGACCAGACCAATCATCAGGAT  
ER beta fwd CTACAGAGAGATGGTCAAAAGTGGA Möller et al., 2009 
 rev GGGCAAGGAGACAGAAAGTAAGT  
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Western Blotting 
Frozen liver tissue was powdered and homogenized in lysis buffer (50 mM Tris pH 8.0, 2 
mM CaCl2, 80 mM NaCl, 1 % Triton-X 100) containing protease inhibitor PMSF (10 mM, 
phenylmethanesulfonylfluoride). Protein concentration was measured by the method of 
Lowry using Bio-Rad (DC Protein Assay, Bio-Rad, Munich, Germany) reagents with BSA 
as standard. Equal amounts of sample (25 µg) were loaded onto 4–12 % Bis-Tris 
NuPAGE® gels (Life Technologies GmbH, Darmstadt, Germany). Following 
electrophoresis, proteins were transferred onto nitrocellulose membranes (Hartenstein, 
Würzburg) and blocked with 5 % non-fat milk in Tris buffered saline solution containing 
0.1 % Tween 20 (TBST, 100 mM; pH 7.4) at room temperature for 1 h. The immobilized 
proteins were detected using specific antibodies against ER beta (sc-8974, Santa Cruz 
Biotechnology, Inc., Heidelberg, Germany), diluted 1:400 in TBST or FAS (ab22759, 
abcam, Cambridge, United Kingdom), and diluted 1:400 in TBST. As a loading control 
beta-actin (Millipore GmbH, Schwalbach/Ts, Germany), diluted 1:15.000 in TBST was 
used. Membranes were incubated with primary antibody solution overnight at 4 °C and 
subsequently rinsed with TBST (four times for 5 min each). As secondary antibodies a 
polyclonal swine anti-rabbit antibody (P0217, Dako, Glostrup, Denmark) or a polyclonal 
rabbit anti-mouse antibody (P0260, Dako), in each case HRP-conjugated and diluted 
1:1000 in TBST, was used. After four more washing steps with TBST blot signals were 
visualized with the Lumi-Light Plus Western Blotting Substrate (Roche Diagnostics, 
Mannheim, Germany) and a FluorChem digital imaging system (Alpha Innotech, CA, 
USA). FAS protein bands were quantified by densitometric analysis using ImageJ 1.38 
sofware (National Institute of Health, USA, http://rsb.info.nih.gov/ij/). Expression levels of 
the reference protein beta-actin were calculated to account for non-homogenous protein 
loading.  
As a positive control of ER beta detection, HCEC cells (SV40 large T antigen-
immortalized human colon epithelial cells) were used that were kindly provided by Prof. 
Pablo Steinberg of the University of Veterinary Medicine Hannover, Foundation. 
 
Hepatic and soleus muscle TG content 
Frozen tissues of liver and soleus muscle (~100 mg) were pulverized in liquid nitrogen and 
lysed in lysis buffer (50 mM Tris pH 8.0, 2 mM CaCl2, 80 mM NaCl, 1% Triton-X 100, 
1 mM PMSF). After homogenization and incubation on ice for 30 min, the lysates were 
centrifuged (15 min, 4 °C, 13000 rpm) and the TG content was analyzed in the 
supernatants by colorimetry using ABX Pentra reagent (ABX Diagnostics Montpellier, 
France). In the same supernatants, the total amount of protein was measured using the 
Lowry method (DC Protein Assay, Bio-Rad, Munich, Germany). 
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Stable isotope ratio analysis 
2.5 h before decapitation the rats received an oral application of 13C labeled glucose (2 
g/kg b.wt.), enriched to +140 ‰ δ13CVPDB. 50 mg of the frozen liver was homogenized and 
dehydrated. All samples were enclosed in tin capsules and analysed by EA-IRMS using 
an elemental analyser (Eurovektor EA 3000, Hekatech, Wegberg, Germany) coupled to a 
continuous-flow isotope ratio mass spectrometer (Delta C, Finnigan, Bremen, Germany). 
Carbon isotope ratios are expressed in per mill relative to VPDB: δ13C [‰]  = 
[(RSample/RStandard) – 1] · 10
3 with R is the 13C/12C ratios (Coplen, 2011). Reference gases 
(CO2, purity 5.3 from Linde, Munich, Germany) were calibrated using the reference 
materials IAEA-CH-6 and IAEA-CH-7. Within the measurements, creatine-monohydrate 
from one batch was used as a working standard. The standard deviation of repeated 
measurements of working standard or samples was 0.1 ‰. Isotope ratios were calculated 
using the ISODAT NT software (version 2.0, Finnigan, Bremen, Germany).  
 
Determination of insulin, serum glucose, and calculation of the HOMA-Index  
Serum was obtained by centrifugation at 4 °C and 3000 x g and stored at − 20 °C. The 
serum concentration of insulin was measured in duplicates using ELISA kits for rats 
according to the manufacturer’s instruction (80-INSRTU, ALPCO Diagnostics, Salem, NH 
03079, USA). Serum levels of glucose were analyzed by colorimetry using reagents from 
DIALAB (Wiener Neudorf, Austria). To measure the serum glucose a chemistry analyzer 
(Roche Hitachi Cobas Mira Plus) was used. Homeostasis Assessment Model (HOMA)–
Index was calculated using the following formula: HOMA–Index = Insulin (fasting, µU/ml) x 
blood glucose (fasting, mg/dl) / 405.  
 
Statistical analysis  
Except IRMS data, statistical significance of differences was calculated using Kruskal–
Wallis one-way analysis of variance with a subsequent Mann–Whitney U-test (SPSS 
Statistical Analysis System, Version 20.0).  
IRMS data were analysed by means of LME models (Pinheiro, 2000). The software 
was R in the latest version (R Development Core Team, 2011). LME analysis required the 
nlme library (Pinheiro, 2011). Treatment (OVX, SHAM) and substitution, respectively, 
represented the fixed effects. Random effects were assumed for the different individuals. 
This was required because duplicate analyses were performed. The magnitude of random 
variation was allowed to vary between different treatment levels. The significance of this 
effect was investigated by means of likelihood statistics. 
Statistical significance was established at p≤0.05.  
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Results 
 
mRNA expression of SREBP-1c, FAS, LPL, and PPAR gamma in adipose tissue 
Several genes are involved in the regulation of lipogenesis, adipocyte differentiation, and 
lipid storage in adipose tissue. The gene FAS encodes a multi-domain enzyme, which is 
important for de-novo lipogenesis, whereas the transcription factor SREBP-1c regulates 
the expression of FAS in response to feeding and insulin (Horton et al., 2002). In adipose 
tissue, the nuclear receptor and transcription factor PPAR gamma is highly expressed and 
induces fatty acid uptake, adipogenesis, and leads to lipid repartitioning into adipose 
tissue from skeletal muscle and liver (Anghel et al., 2007; Vacca et al., 2011). Further, 
LPL as a target gene of PPAR gamma promotes TG formation in adipocytes through 
uptake of circulating lipids (Wong and Schotz, 2002). Substitution of OVX HF rats with E2, 
Alpha or Beta significantly decreased the expression of SREBP-1c, FAS (Fig. 8A and B), 
PPAR gamma, and LPL (Fig. 9A and B) as compared with untreated OVX HF animals. 
The administration of Gen did not show a significant effect on these investigated genes. 
While animals on HF diet showed a general decrease in the mRNA expression of FAS 
and LPL compared to animals on LF diet this effect was not observed regarding SREBP-
1c and PPAR gamma expression. 
 
mRNA expression of SREBP-1c, FAS, and PPARs in liver and soleus muscle 
E2, ER subtype-selective agonists, and genistein also affected the expression of SREBP-
1c and FAS in liver and soleus muscle. In agreement to the observed results in the 
adipose tissue, ovariectomy led to a general increase of SREBP-1c mRNA expression 
compared to SHAM animals in both tissues. Treatment with E2, Alpha, and Beta markedly 
antagonized the OVX induced increase of SREBP-1c mRNA (Fig. 8C and E). The down-
regulation of SREBP-1c mRNA was again associated with a decreased mRNA expression 
of its target gene FAS in the appropriate animal groups (Fig. 8D and F). Interestingly, the 
expression of both lipogenic genes was also reduced by administration of Gen, although 
the effect on the SREBP-1c level in the soleus muscle was statistically not significant. 
Similar to expression in adipose tissue, FAS mRNA expression in liver was lower in 
animals on HF diet compared to rats on LF diet. Conversely, mRNA expression of FAS in 
muscle and SREBP-1c in both tissues was higher in animals fed with the HF diet than with 
the LF diet.  
The mRNA expression of PPAR alpha in both tissues and PPAR delta in the soleus 
muscle were measured as markers for fatty acid utilization. In contrast to the lipogenic 
genes SREBP-1c and FAS, no significant changes on hepatic and muscular mRNA 
expression of PPAR alpha and PPAR delta were detected (data not shown). 
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Because of the improved insulin sensitivity by PPAR gamma activation, indicated by a 
reduced gluconeogenesis in the liver and an increased glucose uptake into the muscle 
(Vacca et al., 2011), the mRNA expression of PPAR gamma in liver and soleus muscle 
was measured. In both tissues, untreated OVX rats on the LF as well as the HF diet 
showed significantly higher mRNA levels of PPAR gamma than the appropriate SHAM 
groups. Application of E2 and Alpha to OVX HF rats antagonized this OVX effect. 
Treatment with Beta and Gen had no significant influence on the mRNA level of PPAR 
gamma as compared to OVX HF animals. Long-term exposure to the fat-enriched diet had 
an additive effect on PPAR gamma expression in the liver of SHAM and untreated OVX 
animals compared to SHAM and OVX animals on LF diet (Fig 9C). In the soleus muscle, 
the additive effect of the HF diet was only observed in SHAM animals, whereas untreated 
OVX animals on the HF diet revealed significantly lower PPAR gamma mRNA levels than 
OVX animals on the LF diet (Fig. 9E).  
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Fig. 8. Effects of E2, ER subtype-selective agonists and Gen on the relative mRNA expression of 
SREBP-1c and FAS in (A and B) adipose tissue, (C and D) liver, and (E and F) soleus muscle after 
10 weeks of treatment. 
SHAM = sham-operated, OVX = ovariectomized, E2 = treated with 17beta-estradiol, Alpha = 
treated with ER alpha-selective agonist, Beta = treated with ER beta-selective agonist, Gen = 
treated with genistein, LF = low fat diet, HF = high fat diet. Data shown are means ± SD for n=7. 
asterisk (*) marks values significantly different from OVX HF or as indicated by lines. Statistical 
significance was established at p ≤ 0.05.  
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Stable isotope ratio analysis in the liver 
To measure the glucose tolerance of the liver in the animals on a HF diet, IRMS was 
performed. Relative to SHAM animals, ovariectomy resulted in a significant increase of 
the mean δ13C. In comparison to untreated OVX animals, treatment with E2 or Alpha 
resulted in significant 13C depletion. Gen treatment resulted in noteworthy depletion, but 
this effect was not statistically significant (p=0.083). The effect of Beta treatment was 
hardly detectable and statistically not significant (Fig. 9D). 
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Fig. 9. Effects of E2, ER subtype-selective agonists and Gen on the relative mRNA expression of 
(A) PPAR gamma and (B) LPL in the adipose tissue as well as (C) PPAR gamma expression in 
liver, and (E) muscle after 10 weeks of treatment. (D) Effects on hepatic glucose uptake in animals 
on HF diet are shown. 
SHAM = sham-operated, OVX = ovariectomized, E2 = treated with 17beta-estradiol, Alpha = 
treated with ER alpha-selective agonist, Beta = treated with ER beta-selective agonist, Gen = 
treated with genistein, LF = low fat diet, HF = high fat diet. Data shown are means ± SD in the case 
of mRNA expression levels. Boxplots (E) are depicted as minimum, 25th, 50th (median), 75th 
percentile and maximum of the distribution (n=7). Asterisk (*) marks values significantly different 
from OVX HF or as indicated by lines. Statistical significance was established at p ≤ 0.05. 
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mRNA expression of ER alpha and ER beta in liver, adipose tissue, and soleus muscle 
To investigate ER subtype expression in liver, adipose tissue, and soleus muscle of the 
animals, RT-PCRs were performed. Specific amplicons for ER alpha (382 bp) and ER 
beta (215 bp) were detected in all three tissues and in all animal groups (Fig. 10A, C, and 
D, depicted are representative results of ER alpha and ER beta mRNA expression 
(untreated OVX and E2-treated OVX animals in each case). The mRNA expression of ER 
beta was lower in all three tissues when compared to ER alpha expression (indicated by 
weaker signals on the gel). Especially in the liver, the expression level of ER beta was 
low, but detectable in each case.  
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Fig. 10. mRNA expression of ER alpha and ER beta in (A) liver, (C) adipose tissue, and (D) soleus 
muscle. Shown are expression in untreated OVX and E2-treated animals on HF diet. (B) Protein 
expression of ER beta in liver is shown in all animals on HF diet (n=7). 
HCEC cell line was used as a positive control for ER beta protein expression. SHAM = sham-
operated, OVX = ovariectomized, E2 = treated with 17beta-estradiol, Alpha = treated with ER 
alpha-selective agonist, Beta = treated with ER beta-selective agonist, Gen = treated with 
genistein, HF = high fat diet, HCEC = SV40 large T antigen-immortalized human colon epithelial 
cells that express ER beta. 
 
CHAPTER THREE 
 
 
 
52 
 
Protein expression of FAS and ER beta in liver 
Western blotting with specific antibodies against FAS and ER beta confirmed the mRNA 
results on the respective mRNA expression in the liver. FAS protein expression pattern 
was down-regulated by treatment with the estrogenic compounds compared to untreated 
OVX animals on HF diet (Fig. 11). Further, the expression level of ER beta was similar in 
all animal groups on a HF diet (Fig. 10B). The specificity of the ER beta antibody used 
was previously tested by using different cell lines in our laboratory (http://docserv.uni-
duesseldorf.de/servlets/DocumentServlet?id=24043). 
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Fig. 11. Effects of E2, ER subtype-selective agonists and Gen on hepatic FAS protein expression 
in animals on HF diet after 10 weeks of treatment (n=7). 
Shown is one representative blot from four consecutive blots with the associated densiometric 
analysis. SHAM = sham-operated, OVX = ovariectomized, E2 = treated with 17beta-estradiol, 
Alpha = treated with ER alpha-selective agonist, Beta = treated with ER beta-selective agonist, 
Gen = treated with genistein, HF = high fat diet. Statistical significance was not established. 
 
TG content in liver and soleus muscle 
Untreated OVX rats revealed higher hepatic triglyceride values compared to the SHAM-
operated groups. A combination of ovariectomy and HF diet showed the highest level of 
hepatic triglycerides. Treatment with E2, Alpha, and Beta significantly antagonized this 
increase, whereas treatment with genistein had only a small effect (Fig. 12A). In the 
soleus muscle, the TG content showed a similar pattern. The highest TG content was 
measured in untreated OVX rats on the HF diet. SHAM animals and OVX animals 
substituted with E2, Alpha, Beta, or Gen showed lower TG concentrations within the 
soleus muscles, although the differences were not significant (Fig. 12B).  
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hepatic triglyceride content
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Fig. 12. Effects of E2, ER subtype-selective agonists and Gen on the TG content in (A) liver and 
(B) soleus muscle after 10 weeks of treatment. 
SHAM = sham-operated, OVX = ovariectomized, E2 = treated with 17beta-estradiol, Alpha = 
treated with ER alpha-selective agonist, Beta = treated with ER beta-selective agonist, Gen = 
treated with genistein, LF = low fat diet, HF = high fat diet. Data are depicted as minimum, 25th, 
50th (median), 75th percentile and maximum of the distribution, empty circles display outliers (n=7 
in liver and n=6 for OVX HF+Beta and n=7 for remaining groups in soleus muscle). Asterisk (*) 
marks values significantly different from OVX HF or as indicated by lines. Statistical significance 
was established at p ≤ 0.05. 
 
Serum levels of insulin and glucose as well as calculation of the HOMA-Index 
Serum levels of glucose and insulin were measured as well as the HOMA-Index was 
calculated, because obesity is associated with an impaired systemic sensitivity to glucose 
and insulin. In spite of different hormonal treatments and diets, all animals were 
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normoglycemic after the experimental period (data not shown). In contrast, measurement 
of serum insulin showed the highest concentration in the untreated OVX animals (OVX 
LF, OVX HF), whereas in all other groups the insulin level was at least 30 % lower (Fig. 
13A). The HOMA-Index, a mathematical model of the glucose-insulin feedback system, 
revealed also the highest values in the untreated OVX animals (Fig. 13B).  
SHAM LF    OVX LF   SHAM HF  OVX HF  OVX HF  OVX HF  OVX HF  OVX HF  
+E2      +Alpha      +Beta      +Gen
serum insulin
n
g
/m
l
SHAM LF    OVX LF   SHAM HF  OVX HF  OVX HF  OVX HF  OVX HF  OVX HF  
+E2      +Alpha      +Beta      +Gen
HOMA-Index
A
B
n
g
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l
 
Fig. 13. Effects of E2, ER subtype-selective agonists and Gen on (A) serum level on insulin and (B) 
on the HOMA-Index after 10 weeks of treatment. 
SHAM = sham-operated, OVX = ovariectomized, E2 = treated with 17beta-estradiol, Alpha = 
treated with ER alpha-selective agonist, Beta = treated with ER beta-selective agonist, Gen = 
treated with genistein, LF = low fat diet, HF = high fat diet. Data are depicted as minimum, 25th, 
50th (median), 75th percentile and maximum of the distribution for n=6 (OVX HF+Beta) and n=7 
(remaining groups). Empty circles display outliers. No significant differences in serum insulin or 
HOMA-Index were found between the groups. 
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Discussion 
 
In the present study, the molecular mechanisms of ER alpha- and ER beta-mediated 
effects on fat and glucose metabolism in adipose tissue, liver, and skeletal muscle were 
investigated. Obese OVX Wistar rats were treated with ER subtype-selective agonists. In 
addition, a subset of OVX animals received a diet enriched with the phytoestrogen Gen in 
a relatively high dosage. Here, the aim was to find out whether Gen is able to induce 
effects similar to those of estrogens. 
Three major results are presented in this study: treatment with either ER subtype-
selective agonist resulted in a decrease of lipogenesis and adipogenesis in adipose 
tissue. Alpha as well as Beta treatment decreased lipogenesis in liver and soleus muscle 
and lowered TG accumulation in both tissues. Systemic insulin sensitivity was improved 
by activation of ER alpha but also by ER beta, most likely because of the anabolic activity 
of ER beta. 
 
Lipogenesis and adipogenesis is decreased via either ER subtype-selective agonist in 
adipose tissue 
In adipose tissue, the expression of lipogenic (SREBP-1c and FAS) and adipogenic genes 
(PPAR gamma and LPL) was significantly decreased in E2-, Alpha-, and Beta-treated 
OVX HF animals compared to untreated OVX HF rats (Fig. 8A and B and Fig. 9A and B). 
These findings are in line with previous results of our group and others demonstrating that 
estrogens (e.g., E2) reduce the development of adiposity (Bryzgalova et al., 2008; D'Eon 
et al., 2005; Weigt et al., 2012; Zoth et al., 2010; Zoth et al., 2012). Further, these results 
are consistent with observations in postmenopausal women who tend to accumulate more 
fat in total than perimenopausal women do with a simultaneous alteration in fat distribution 
from the lower body segment to the upper body (Cooke and Naaz, 2004; Ley et al., 1992). 
The previous study demonstrated that activation of either ER subtype decreases 
visceral fat mass, adipocyte size, and circulating leptin concentration. Interestingly, the 
amount of energy intake was not significantly affected by any treatment (Weigt et al., 
2012). The present study shows for the first time that expression of genes associated with 
lipogenesis (FAS and SREBP-1c) and adipogenesis (PPAR gamma and LPL) were 
inhibited by treatment with both ER subtype-selective agonists. These results confirmed 
the observed inhibition of lipogenic genes (SREBP-1c and FAS) by treatment of OVX 
animals with E2, which was described before in two other animal studies (Bryzgalova et 
al., 2008; D'Eon et al., 2005). The role of ER alpha and ER beta in this context has been 
controversially discussed. Several studies have shown that either ER subtype is able to 
modulate fat homeostasis. As described in detail in the introduction, deficiency of ER 
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alpha results in increased visceral fat mass suggesting that ER alpha is critical in adipose 
tissue biology (Heine et al., 2000). However, an anti-lipogenic action of ER beta was 
demonstrated in a study conducted with βERKO mice, based on negative cross talk with 
PPAR gamma in adipocytes (Foryst-Ludwig et al., 2008). The expression of LPL, a target 
gene of PPAR gamma (Wong and Schotz, 2002), was suppressed by ER beta (Foryst-
Ludwig et al., 2008) and also by ER alpha (Homma et al., 2000). Thus, taken together, 
both ER subtypes may be involved in adipose tissue biology (recently reviewed also by 
Faulds and colleagues (Faulds et al., 2012)) and by (at least partly) similar molecular 
mechanisms. 
The higher body weight and fat content in αERKO mice compared to wild types was 
attributed to increased food intake and lipogenesis in adipose tissue and liver (Bryzgalova 
et al., 2006; Homma et al., 2000) as well as impaired insulin sensitivity and glucose 
tolerance in liver, skeletal muscle, and adipose tissue (Barros et al., 2009; Barros et al., 
2006; Bryzgalova et al., 2006). An increased body weight and fat mass compared to wild 
types was also observed for βERKO mice. Here an up-regulation of PPAR gamma in the 
presence of improved insulin sensitivity was discussed as the relevant molecular 
mechanism (Foryst-Ludwig et al., 2008). In light of the results presented here, a further 
explanation for the increased body weight in βERKO mice could be an altered body 
composition. In the previous study, anabolic activity of ER beta was demonstrated. ER 
beta activation resulted in significantly larger soleus muscle fiber sizes (Weigt et al., 
2012). The specific role of ER beta in muscle growth and repair was also shown in an 
animal study by using the ER subtype-selective agonists and βERKO mice in a model of 
toxin-induced skeletal muscle damage (Velders et al., 2012). Here the ER beta-selective 
agonist accelerated the regeneration of damaged skeletal muscles in female rats and 
displayed anabolic potency in a classical Hershberger assay. In addition, serum creatine 
kinase activity after notexin treatment was highest in βERKO mice compared to αERKO 
and wild types while markers such as embryonic myosin heavy chain (muscle cell 
regeneration) were lowest in βERKO animals. Therefore, it can be hypothesized that 
βERKO mice utilize lipids and glucose less efficient than wild type counterparts due to a 
lower muscle mass that subsequently result in an increased body weight and fat mass. 
 
Lipogenesis is decreased via both ER subtype-selective agonists and Gen in liver and 
soleus muscle 
In this study, treatment with E2, Alpha, Beta, and less pronounced with Gen decreased 
the expression of lipogenic genes (SREBP-1c and FAS) in liver and soleus muscle 
compared to untreated HF controls (Fig. 8C-F). The same pattern was observed for FAS 
protein expression in the liver (Fig. 11). This is in agreement with the observed down-
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regulation of these genes by E2 (Bryzgalova et al., 2008; D'Eon et al., 2005). In αERKO 
mice, expression of lipogenic genes were increased compared to wild types, suggesting a 
functional involvement of ER alpha is responsible for the effect (Bryzgalova et al., 2006). 
However, the role of ER beta was not investigated in their study. The study presented 
here, shows for the first time that an ER beta-selective agonist was able to mediate a 
down-regulation of these lipogenic genes also in the liver. This is confirmed by the 
observation that both ER subtype-selective agonists mediated a similar anti-lipogenic 
effect in the soleus muscle.  
Several studies report that the liver primarily expresses the ER alpha, whereas the ER 
beta subtype is absent or expressed only at low levels (Matthews and Gustafsson, 2003; 
Taylor and Al-Azzawi, 2000). However, in the present study the analysis of hepatic mRNA 
expression of ER beta clearly demonstrated that this ER subtype is expressed in rat liver 
tissue (Fig. 10A) and confirms the work of Maruyama and colleagues that showed the 
expression of two ER beta isoforms in different rat tissues including the liver (Maruyama 
et al., 1998). The expression of ER beta in liver was also confirmed on protein level (Fig. 
10B). Therefore, it can be suggested that the anti-lipogenic effects observed in the Beta-
treated animals are mediated via ER beta. 
To make the story even more complex: it has been shown that some membrane 
responses to estrogens require both ER alpha and ER beta to be initiated (Levin, 2011). 
This aspect has to be investigated in more detail in future studies. However, in the animal 
model used in this study, the E2-treated rats did not show an increased response of the 
investigated parameters compared to rats treated with the ER subtype-selective agonists.  
Interestingly, mRNA expression levels of markers associated with fatty acid transport 
and utilization were not significantly affected between the respective treatment groups in 
liver and soleus muscle (data not shown). In both tissues, mRNA expression levels of 
PPAR alpha were analyzed. Additionally, PPAR delta mRNA expression was measured in 
the soleus muscle. The PPAR alpha has been identified to regulate fatty acid utilization 
and the first PPAR response element (PPRE) was found in the 5’-flanking sequence of the 
rat acyl-CoA oxidase (Tugwood et al., 1992). This transcription factor is predominantly 
expressed in the liver, but also in other tissues such as heart, kidney and skeletal muscle 
(Fruchart, 2007; Tobin and Freedman, 2006). In skeletal muscle, PPAR delta is highly 
expressed (10–50 fold higher than PPAR alpha or PPAR gamma) and also contributes to 
fatty acid transport and oxidation (Braissant et al., 1996).  
Taken together, lipogenic genes are up-reglated in liver and soleus muscle of untreated 
OVX animals, while the utilization of fatty acids seems to be unaffected compared to 
SHAM and substituted OVX groups.  
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TG accumulation is decreased via either ER subtype-selective agonist in liver and soleus 
muscle 
In this study, untreated OVX animals on HF diet showed the highest hepatic TG content. 
This is in line with hepatic up-regulation of lipogenic genes (SREBP-1c and FAS) and 
PPAR gamma expression (associated not only with improved insulin sensitivity (Vacca et 
al., 2011), but also with higher lipid accumulation (Way et al., 2001)). SHAM, E2-, Alpha-, 
and Beta-treated animals accumulated significantly less triglycerides in liver. Gen 
treatment had no significant effect (Fig. 12A). A similar pattern was observed in the soleus 
muscle, although the effect was not statistically significant (Fig.12B). Thus, untreated OVX 
animals revealed increased lipogenesis and adipogenesis in adipose tissue as well as 
enhanced lipogenesis and TG accumulation in liver and soleus muscle than the SHAM, 
E2-, Alpha-, and Beta-treated animals. Gen treatment showed at least the same tendency 
in liver and soleus muscle. These findings are of great importance, because fat 
accumulation within non-adipose tissues as well as obesity itself is associated with a high 
risk of developing insulin resistance and T2DM (Shimabukuro et al., 1997; Unger, 1995). 
 
Insulin sensitivity  
In this study, ovariectomy markedly increased PPAR gamma mRNA expression compared 
to SHAM animals in liver and soleus muscle. In animals on HF diet, this effect was 
antagonized by treatment with E2 and Alpha but not by Beta and Gen (Fig 9C and E) and 
thus appears to be mediated via ER alpha. This is in agreement with literature data 
showing that E2 down-regulates PPAR gamma expression (Bryzgalova et al., 2008). The 
rate of hepatic glucose uptake, determined by IRMS, in animals on a HF diet fits to the 
observed PPAR gamma expression pattern. A significantly higher glucose uptake in the 
untreated OVX HF animals was observed compared to SHAM, E2-, and Alpha-treated 
animals (Fig. 9D).  
However, Beta decreased PPAR gamma expression in adipocytes (Fig. 9A). These 
divergent observations between tissue types may be explained by the different functions 
of PPAR gamma in adipose tissue compared to liver and skeletal muscle, as follows. 
PPAR gamma is highly expressed in white adipose tissue (Escher et al., 2001), and 
induces primarily adipogenesis and lipid repartition (Vacca et al., 2011). In liver and 
skeletal muscle PPAR gamma activation improves insulin sensitivity (Kim and Ahn, 2004; 
Vacca et al., 2011; Way et al., 2001). In liver cells, PPAR gamma activation increases 
insulin sensitivity through inhibition of genes involved in gluconeogenesis (i.e., PEPCK, 
pyruvat carboxylase, and glucose-6-phosphatase) (Davies et al., 1999; Way et al., 2001) 
and induces the hepatic expression of glucokinase (the rate limiting enzyme in glycolysis), 
and the hepatic glucose transporter (Kim and Ahn, 2004; Way et al., 2001). In skeletal 
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muscle, it has been demonstrated that stimulation of PPAR gamma expression increases 
glucose uptake and insulin sensitivity via stimulation of the AMP-activated protein-kinase 
(Vacca et al., 2011), a kinase that is also activated by E2 via non-genomic pathways 
(D'Eon et al., 2005). Taken together, PPAR gamma expression patterns in liver and 
soleus muscle and hepatic glucose uptake measurement suggest improved insulin 
sensitivity in untreated, Beta-, and Gen-treated OVX animals compared to SHAM, E2-, 
and Alpha-treated rats. However, according to the literature, insulin sensitivity is improved 
in the presence of E2 exclusively activating ER alpha (Barros et al., 2009; Barros et al., 
2006; Bryzgalova et al., 2006; Heine et al., 2000; Ropero et al., 2008). Thus, by showing 
that PPAR gamma activation and glucose uptake in liver and soleus muscle is stimulated 
by ER beta, this study presents contradictory findings compared to other published data 
(as described above).  
The contradicting results might be explained by comparing the PPAR gamma 
expression with the blood lipid pattern that was also assessed. Stimulation of PPAR 
gamma in liver and skeletal muscle is associated with increased lipogenesis as well as 
decreased fatty acid oxidation (Way et al., 2001). It therefore contributes to fatty acid 
production and storage.  
The increased hepatic PPAR gamma expression in the untreated OVX HF group 
compared to SHAM, E2-, and Alpha-treated animals is in agreement with the effects on 
blood lipid levels that were observed in the previous study. The untreated OVX animals 
showed significantly higher levels of TC, LDL, and VLDL compared to SHAM animals and 
treatment with E2 and Alpha antagonized the OVX-induced effect in animals on HF diet. 
The levels of TC, LDL, and VLDL in the Beta- and Gen-treated animals were not 
significantly reduced (Weigt et al., 2012). These findings correspond with the PPAR 
gamma expression in this study. Increased PPAR gamma activation may also promote 
higher fat accumulation and VLDL assembly in the liver.  
Therefore, it can be hypothesized that the up-regulation of PPAR gamma (at least) in 
untreated OVX rats could be a mechanism to compensate the high accumulation of lipids 
in non-adipose tissues that is associated with impaired insulin sensitivity. This hypothesis 
is underlined by the systemic insulin sensitivity in the animals, which was analyzed by 
measuring serum insulin levels and calculation of the HOMA-Index. Whereas serum 
glucose levels revealed no significant differences between the animal groups (data not 
shown), the concentration of serum insulin was higher in the untreated OVX animals than 
in the SHAM and substituted OVX animals (Fig. 13A). These results are in line with the 
calculated HOMA-Index, a model that is used to estimate the degree of insulin sensitivity 
(Fig. 13B). Hence, untreated OVX animals may need higher concentrations of insulin 
compared to the other groups to achieve similar serum glucose concentrations. This may 
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indicate that untreated OVX animals have decreased insulin sensitivity and that excessive 
accumulation of intracellular lipids is strongly associated with impaired insulin sensitivity.  
In light of the rather complex regulation of glucose sensitivity and blood lipids, data 
obtained in this study indicate that PPAR gamma expression, blood lipids, and glucose 
uptake in Beta- and Gen-treated rats is similar to untreated animals. However, systemic 
insulin sensitivity in these animals was comparable to SHAM, E2- and Alpha-treated 
animals. Therefore, it can be hypothesized that Beta-treated animals, due to increased 
muscle mass, may have an improved utilization of lipids and glucose in the muscle. This 
contributes to a clearance of TG-rich lipoproteins from the bloodstream and thus to a 
lower deposition of lipids in adipose or non-adipose tissues. Untreated OVX rats may lack 
this ability and therefore tent to accumulate fat in liver and muscle despite PPAR gamma 
activation in adipocytes.  
The results presented here suggest a specific role of ER beta in skeletal muscle 
homeostasis that results in a favorable body composition (higher muscle/fat ratio) with 
regard to utilization of lipids and glucose and insulin sensitivity. Compounds that 
selectively target ER beta might therefore provide new therapeutic concepts for diseases 
such as T2DM and the metabolic syndrome. 
 
Genistein 
In line with the previous results, treatment with Gen had no significant effects on the 
investigated parameters in adipose tissue. This may be due to the fact that Gen and its 
metabolites may be present only in low concentrations in this tissue, which needs to be 
verified by determination of tissue concentrations. In liver and soleus muscle, application 
of Gen to OVX HF rats led to less pronounced but similar effects as treatment with Beta. 
Gen-treated animals also showed reduced lipogenesis and TG content in liver and 
muscle, and a PPAR gamma mRNA expression, glucose uptake and blood lipid 
composition pattern that was similar to Beta-treated animals.  
The dose of Gen used was relatively high - a human equivalent dose (Reagan-Shaw 
et al., 2008) can be reached by a daily dose which is two to four times higher than the 
maximum dose commonly used for postmenopausal treatment (Andres and Lampen, 
2012; Hooper et al., 2010; Messina and Wood, 2008; Steinberg et al., 2011; Wei et al., 
2012). Since Gen was given orally in the present study, Gen and resulting metabolites 
may act in a synergistic manner. Moreover, tissue concentrations of Gen and its 
metabolites may differ depending on tissue type. In contrast to Alpha and Beta – at the 
given doses – Gen binds to both receptors, although a preferential binding affinity to ER 
beta has been shown (Kuiper et al., 1998). Therefore dependent on the expression ratios 
of ER alpha and beta in a respective tissue it may act more as an ER alpha or ER beta 
CHAPTER THREE 
 
 
 
61 
 
selective agonist. This has been demonstrated in a variety of previous studies from our 
group (Hertrampf et al., 2007; Schleipen et al., 2011; Velders et al., 2012).  
The pronounced activity of Gen in these tissues may be due to pharmacokinetic 
aspects: e.g., the concentration of Gen in the liver may be higher than in other tissues. In 
the skeletal muscle, Gen’s ability to activate ER beta-specific mechanisms such as 
anabolic effects may be relevant. In a recent publication of our group (Velders et al., 2012) 
it was demonstrated that Gen activates anabolic mechanisms in the skeletal muscle 
similar to Beta. Therefore, similar to treatment with Beta, Gen-treated animals may 
improve their energy homeostasis through enhanced utilization of glucose and lipids. 
 
Impact of the HF diet 
In general, the HF diet fed to the animals in this study was used to induce obesity. This 
approach made is possible to examine the impact of hormonal treatment on obese OVX 
rats. The LF diet used in the study served as control and was only fed to SHAM and 
untreated OVX animals. In the previous study, higher gain of body weight and visceral fat 
mass were observed comparing SHAM and OVX animals on HF diet with SHAM and OVX 
animals on LF diet respectively, but the differences were statistically not significant (Weigt 
et al., 2012). In this study, no significant differences were observed between the two diets 
in SHAM and untreated OVX animals on hepatic and muscular TG content as well as 
serum levels of insulin, although animals on the fat-enriched diet tended to higher values 
similar to the previous study. Therefore, after an experimental period of 10 weeks the loss 
of ovarian function resulted in effects that were more adverse regarding the above-
mentioned parameters than the fat-enriched diet. However, on the molecular level diet-
induced effects were more pronounced. In adipose tissue and liver, mRNA expression of 
FAS was significantly down-regulated in SHAM and untreated OVX animals (only in 
adipose tissue) on HF diet compared to the same animal groups fed with the LF diet. This 
effect can be most likely attributed to the high content of fat in the diet, which seems to 
result in a general down-regulation of de novo lipogenesis in both tissues. Significant 
effects between the two diets were also observed on mRNA expression levels of SREBP-
1c (in adipose tissue and liver) and PPAR gamma (in adipose tissue, liver, and soleus 
muscle), whereby here the HF diet resulted in an higher mRNA expression levels 
compared to the mRNA levels in animals on LF diet. The higher expression level of PPAR 
gamma in animals on the fat-enriched diet could be again a mechanism to compensate 
the high accumulation of lipids and to increase insulin sensitivity. 
 
 
CHAPTER THREE 
 
 
 
62 
 
Conclusion 
 
In summary, the data presented here provide evidence that estrogens down-regulate 
lipogenic and adipogenic genes through either ER subtype in adipose tissue. 
Furthermore, in liver and soleus muscle, treatment with all estrogenic compounds 
decreased expression of lipogenic genes and lowered TG accumulation compared to 
untreated OVX HF animals. Hepatic and muscular insulin sensitivity appears to be 
increased in untreated, Beta-, and Gen-treated animals (similar patterns of PPAR gamma 
expression and glucose uptake). Because systemic insulin sensitivity was most restricted 
in untreated OVX animals on HF diet, these rats might compensate for increased levels of 
intracellular lipids by up-regulating PPAR gamma. This hypothesis is in line with the 
association of intracellular lipid accumulation in non-adipose tissues with T2DM. Further, it 
can be hypothesized that anabolic effects of ER beta may contribute to improved 
utilization of glucose and lipids in Beta- and Gen-treated animals. Thus, lipid and glucose 
metabolism is positively affected by E2 activating either ER subtype. The anti-diabetic 
effects of ER alpha and ER beta seem to be mediated via different molecular mechanisms 
in soleus muscle and liver.  
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Gene name Description Reference
adipose tissue liver soleus muscle
SREBP-1c transcription de-novo -lipogenesis h de-novo -lipogenesis h de-novo -lipogenesis h Horton et al. 2002
factor
FAS target gene of de-novo -lipogenesis h de-novo -lipogenesis h de-novo -lipogenesis h Horton et al. 2002
SREBP-1c
PPAR gamma transcription adipogenesis h gluconeogenesis i glucose uptake h Anghel et al., 2007
factor fatty acid uptake h glucose uptake h insulin sensitivity h Kim and Ahn, 2004
repartition of lipids from insulin sensitivity h lipid accumulation h Way et al., 2001
muscle and liver h lipid accumulation h
LPL target gene of fatty acid uptake Wong and Schotz, 2002
PPAR gamma from circulating lipids h Homma et al., 2000
PPAR alpha transcription fatty acid transport and fatty acid transport and Vacca et al., 2011
factor oxidation h oxidation h
PPAR delta transcription fatty acid transport and Vacca et al., 2011
factor oxidation h
mitochondrial respiration h
Effects of gene activation regarding metabolic homeostasis in
Supplementary material 
 
Table 4. Description of genes that were analyzed by real-time RT-PCR. 
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Abstract 
 
The leptin resistant female Zucker diabetic fatty (ZDF fa/fa) rats are described to be 
hyperphagic and obese, but compared to their male counterparts they remain 
euglycaemic. Since estrogens are known to affect glucose metabolism, the long-term 
effect of treatment with estradiol (E2), the ER subtype-selective agonists (Alpha and 
Beta), and genistein (Gen) was investigated in ovariectomized ZDF rats. After 4 months, 
food intake, body weight, systemic glucose tolerance, and muscular GLUT4 expression as 
well as muscle fiber areas were determined. Additionally, the impact of E2 and Alpha on 
glucose uptake in liver, skeletal muscle, and adipose tissue as well as localization of 
muscular GLUT4 was analyzed. Food intake and body weight were markedly reduced by 
E2 and Alpha treatment. Glucose tolerance was improved by treatment with E2, Alpha, 
Beta, and Gen. Glucose absorbance in liver, skeletal muscle, and adipose tissue was 
accelerated in E2 and Alpha treated animals compared to untreated OVX rats (impact of 
Beta and Gen was not investigated). In skeletal muscle, treatment with Alpha enhanced 
the expression and translocation of GLUT4 to the cell membrane, whereas Beta 
substitution resulted in the largest muscle fiber sizes. Administration of Gen suggested 
affecting both GLUT4 expression and muscle fiber sizes. 
Thus, the data demonstrate that ER alpha mediates decreased food intake and body 
weight in leptin resistant female ZDF rats. Activation of ER alpha and beta improves 
glucose tolerance, but at least in the skeletal muscle via different pathways. Further, the 
ER alpha accelerates the glucose absorbance in liver and adipose tissue. 
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Introduction 
 
In recent years, estrogens have been shown to modulate glucose homeostasis in humans 
and rodents. For example, long-term administration of E2 to OVX rats on standard diet as 
well as on HF diet improved systemic glucose tolerance and insulin sensitivity and 
enhanced insulin signaling in the skeletal muscle (Riant et al., 2009; Saengsirisuwan et 
al., 2009). Further, E2 substitution improved glucose tolerance in a rat model of already 
established obesity, when compared to untreated OVX animals (Zoth et al., 2012). 
Moreover, also aromatase-knockout mice, which do not produce estrogens, were 
described to develop glucose intolerance and insulin resistance (Simpson et al., 2005; 
Takeda et al., 2003). In postmenopausal women, estrogen deficiency is linked to a higher 
risk of developing insulin resistance and T2DM. Hormonal therapies have been shown to 
lower this incidence (Crespo et al., 2002; Curtis and Wilson, 2005; Kanaya et al., 2003; 
Louet et al., 2004). Generally, men display a higher prevalence of impaired glucose 
metabolism, when compared with premenopausal women (Kuhl et al., 2005), which also 
points to the protective role of female sex hormones. 
Estrogens mainly act through two distinct ER subtypes, ER alpha and ER beta that 
belong to the nuclear hormone receptor family. Activated ERs regulate the transcription of 
diverse ER target genes, resulting in a wide range of biological effects. Both ER subtypes 
show distinct tissue and gender specific expression patterns and show differences in the 
three-dimensional structure of their ligand-binding domain. Thus, a range of compounds, 
synthetic or natural origin, selectively activates either ER.  
The role of the two distinct ER subtypes in the molecular mechanisms underlying the 
beneficial role of estrogens in glucose homeostasis is still not completely understood. 
Several studies in ERKO animals have shown that the loss of ER alpha in male and 
female mice lowers glucose tolerance and insulin sensitivity as compared to wild type 
counterparts (Cooke et al., 2001; Heine et al., 2000). This metabolic phenotype was 
attributed to a reduced expression level of GLUT4 in the skeletal muscle and the white 
adipose tissue (Barros et al., 2009; Barros et al., 2006), but also to impaired insulin 
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sensitivity in the liver (Bryzgalova et al., 2006). By contrast, for ER beta a pro-diabetic 
action through a negative cross talk with adipose PPAR gamma was postulated (Foryst-
Ludwig et al., 2008). However, the potency of ER beta to accelerate the regeneration of 
damaged skeletal muscle as well as to increase the skeletal muscle mass was recently 
demonstrated in female rodents (Velders et al., 2012; Weigt et al., 2012). 
The obese Zucker Diabetic Fatty (ZDF fa/fa) rat strain is characterized by 
hyperphagia, hyperleptineamia, and obesity, because of a mutation of the leptin receptor 
that causes an ineffective interaction between leptin and its receptor. Obese male animals 
become hyperglycaemic between 7 and 10 weeks and onset of diabetes is described at 
the age of 12 weeks. Interestingly, female ZDF rats also become obese but they remain 
normoglycaemic. Female ZDF rats only become diabetic when they receive a special fat 
enriched diet (http://www.criver.com/SiteCollectionDocuments/ZDF.pdf). 
It was hypothesized that ovariectomized ZDF rats on normal diet also develop 
impaired glucose tolerance due to hormonal decline, whereas ovary intact females or E2-
substituted OVX rats might be protected. In the present study, this hypothesis was tested 
by using female ZDF rats, which were ovariectomized or SHAM-operated. Groups of OVX 
animals were treated with either E2, ER subtype-selective agonists (Alpha or Beta), or 
genistein to achieve deeper knowledge in the protective role of estrogens on the existing 
gender dimorphism regarding glucose homeostasis in ZDF rats. The ER agonists 
16alpha-LE2 (Alpha) and 8beta-VE2 (Beta) selectively activate ER alpha and ER beta 
respectively (Hillisch et al., 2004). The isoflavone Gen is plant-derived and can activate 
both ER subtypes. After the experimental period, the effects of the estrogenic compounds 
on energy intake, body weight, glucose metabolism, and on the soleus muscle fibers were 
investigated. 
 
 
Materials and methods 
 
Animals 
Juvenile female Zucker diabetic fatty (ZDF fa/fa) rats (6-weeks old, 180–240 g) were 
obtained from Charles River (Charles River Laboratories, Research Models and Services, 
Germany GmbH) and kept at constant room temperature (20 °C ± 1), relative humidity 
(50–80 %) and illumination (12 h light/dark cycles). The animals were housed 3–4 in each 
cage, with food (Purina 5008, SSniff GmbH, Soest, Germany) and water provided ad 
libitum. All animal procedures were approved by the Committee on Animal Care and 
compliant with accepted veterinary medical practice.  
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Animal diet and treatment 
All animals were fed with a soybean free diet (PMI 5008, Ssniff®). Prior to onset of 
experimental procedures, all animals were ovariectomized (OVX) or SHAM-operated 
(SHAM) via the dorsal route. Following two weeks of regeneration and endogenous 
hormonal decline the OVX animals were randomly allocated to treatment and vehicle 
groups (untreated OVX rats). The treatment groups received either E2, Alpha (the ER 
alpha-selective agonist 16 alpha-LE2 (3,17-dihydroxy-19-nor-17alpha-pregna-1,3,5(10)-
triene-21,16alpha-lactone)), Beta (the ER beta-selective agonist 8beta-VE2 (8-vinylestra-
1,3,5(10)-triene-3,17beta-diol)) or Gen. E2 (4 µg/kg b.wt per day), Alpha (10 µg/kg b.wt 
per day), and Beta (100 µg/kg b.wt per day) were applied via ALZET® osmotic mini 
pumps, whereby the substances were dissolved in dimethylsulfoxide and water according 
to the manufacturer’s instructions for filling. Gen was administered via Gen-enriched food 
(about 42 mg/kg b.wt per day). Composition of diets and animal grouping see Table 5 and 
Fig. 14. The treatment doses of the respective substances were chosen based on 
previous experiments (Diel et al., 2004; Hegele-Hartung et al., 2004; Hertrampf et al., 
2009a; Hertrampf et al., 2005; Hertrampf et al., 2008b) and at a dose that ensures 
selectivity for the ER subtype-selective agonists. E2 was provided by Sigma-Aldrich 
(Deisenhofen, Germany) and Gen was obtained from LC Laboratories (Woburn, MA 
01801 USA). Ssniff Spezialdiäten GmbH, Soest, Germany, provided the food enrichment 
with Gen. The two steroidal and highly subtype-selective agonists Alpha and Beta were 
obtained from Bayer Schering Pharma AG, (Berlin, Germany) and detailed information 
about the structure-based design, the synthesis strategy, and the characterization of both 
ligands in vitro and in vivo can be found elsewhere (Hillisch et al., 2004). Throughout the 
treatment period, body weight and food intakes were monitored twice a week. 
After 17 weeks of treatment, the animals were sacrificed by decapitation after light 
anaesthesia with CO2 inhalation and the complete blood was collected. The uteri were 
prepared free of fat and the wet weights were determined. Periovarian fat pads and livers 
were immediately frozen in liquid nitrogen. The soleus and gastrocnemius muscles were 
removed and directly frozen in liquid nitrogen for analysis of molecular markers or 
embedded in TissueTek® (Sakura, Staufen, Germany), cooled in 2-methylbutane, and 
frozen in liquid nitrogen for histological analysis. 
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2 weeks of regeneration +
„hormone decline“
19 weeksstart
group hormone treatment
state E2 Alpha Beta Gen
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2 OVX
3 OVX X
4 OVX X
5 OVX X
6 OVX X  
Fig. 14. Experimental design. 
SHAM = sham operated, OVX =ovariectomized, E2 = treated with 17beta-estradiol, Alpha = treated 
with ER alpha-selective agonist, Beta = treated with ER beta-selective agonist, Gen = treated with 
genistein. 
 
 
Table 5. Composition of the diet.  
PMI5008 without soybean products, sniff Spezialdiäten GmbH, Soest, Germany. 1) physiological 
fuel values 
 
Product No. % of the diet Product No. % of the diet
Wheat 18.205 Crude protein, CP 23.500
Corn, pretreated 22.000 Crude fat 7.900
Wheat bran 16.000 Crude fibre, CF 4.400
Oats, rolled 8.000 Crude ash 6.200
Potato protein 3.000 Starch 33.900
Corn gluten meal 5.000 Sugar 2.900
Fish meal 9.000 S Carbohydrates 46.600
Poultry protein hydrol. SD 5.000
Brewer's yeast 1.000
Whey powder 1.000 Energy (Atwater), MJ/kg 1) 14.900
L-Lysine HCl 0.220 kJ% Protein 26.000
DL-Methionine 0.200 kJ% Carbohydrates 54.000
Choline chloride 0.360 kJ% Fat 20.000
Vitamin & trace element premix 1.100
NaCl, salt 0.500
MCP, calcium phosphate monobasic 0.800 Fatty acids  % of the diet
Calcium carbonate 1.100 C16:0 1.520
Ca propionate 0.400 C18:0 0.590
Sorbic acid 0.100 C20:0 0.020
BHT (Butylhydroxytoluol) 0.015 C16:1 0.220
Lignocellulose 2.000 C18:1 2.460
Sugar beetpulp 1.500 C18:2 n6 1.980
Pork lard 3.500 C18:3 n3 0.140  
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Intraperitoneal glucose tolerance test (ipGTT) 
After 15 weeks of treatment, animals were fasted overnight and blood glucose levels were 
determined. The animals were injected i.p. with glucose solution (1 g/kg b.wt), and blood 
glucose concentration was measured at 15, 30, 60, and 120 min after glucose load. Blood 
samples were analyzed using the ACCU CHECK® Compact Plus Meter Kit (Roche 
diagnostics GmbH, Mannheim, Germany).  
 
Stable isotope ratio analysis 
3.5 h before decapitation two rats of the SHAM, OVX, OVX+E2, and OVX+Alpha animal 
groups received an oral application of 13C labeled glucose (2 g/kg b.wt)2, enriched to +140 
‰ δ13CVPDB. 50 mg of frozen liver, periovarian fat pads, gastrocnemius muscle, and soleus 
muscle of those glucose-substituted animals were homogenized and dehydrated. Same 
procedure was performed with two animals without glucose application from the 
respective groups, which served as negative controls. All samples were enclosed in tin 
capsules and analysed by EA-IRMS using an elemental analyser (Eurovektor EA 3000, 
Hekatech, Wegberg, Germany) coupled to a continuous-flow isotope ratio mass 
spectrometer (Delta C, Finnigan, Bremen, Germany). Carbon isotope ratios are expressed 
in per mill relative to VPDB: δ13C [‰] = [(RSample/RStandard) – 1] · 10
3 (Coplen, 2011) with R 
is the 13C/12C ratio. Reference gases (CO2, purity 5.3 from Linde, Munich, Germany) were 
calibrated using the reference materials IAEA-CH-6 and IAEA-CH-7. Within the 
measurements creatine-monohydrate from one batch was used as a working standard. 
The standard deviation of repeated measurements of working standard or samples was 
0.1 ‰. Isotope ratios were calculated using the ISODAT NT software (version 2.0, 
Finnigan, Bremen, Germany).  
 
Real-time RT-PCR experiments 
Total RNA from the frozen gastrocnemius muscle was extracted using the standard 
TRIzol method (Life Technologies GmbH, Darmstadt, Germany). RNA was quantified by 
spectrophotometry (NanoDrop TM 1000, Thermo Scientific, Wilmington, DE 19810, USA) 
and cDNA was synthesized from 1 µg RNA using a Reverse Transcription System 
(QuantiTect ®, Qiagen). Real-time RT-PCR was performed with Taq DNA polymerase 
(Life Technologies GmbH, Darmstadt, Germany) in the presence of a fluorescent dye 
(SYBR Green, BioRad) on an Mx3005P™ qPCR System (Stratagene). All reactions were 
run in triplicate in a total volume of 50 µl. The PCR program was as follows: 95 °C for 3 
min for 1 cycle, followed by 35 cycles of 30 s at 95 °C, 30 s at 58 °C, 30 s at 72 °C, and 1 
                                                 
2
 Because of a pilot study, the stable isotope ratio analysis was not performed in all animal groups. 
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cycle at 72 °C for 1 min. Fluorescence was quantified during the 58 °C annealing step and 
product formation was confirmed by melting curve analysis (58–95 °C). Relative mRNA 
amounts of target genes were calculated after normalization to an endogenous reference 
gene (Cytochrom c Ocidase, subunit 1A) following the ΔΔCT method (Pfaffl, 2001). Based 
on the genomic sequences available at the UCSC Genome Bioinformatics database the 
specific primer pair for GLUT4 was designed using the software Primer3 (Rozen and 
Skaletsky, 2000) and confirmed by the sequences in the NCBI database 
(http://www.ncbi.nlm.nih.gov/). The primer pair for the reference gene 1A was published 
elsewhere (Höfer et al., 2009). Primers were synthesized by Life Technologies GmbH, 
Darmstadt, Germany: GLUT4_fwd 5-TATTTGGCT TTGTGGCCTTC-3’, GLUT4_rev 5’-
CGGCAAATAGAAGGAAGACG-3’, 1A_fwd 5’-CGTCACAGCCCATGCATTCG-3’, 1A_rev 
5’-CTGTTCATCCTGTTCCAGCTC-3’. 
 
Immunohistochemical staining and visualization of GLUT4 in the gastrocnemius muscle 
The same animals that received an oral application of 13C labeled glucose were used to 
evaluate the distribution of the insulin-dependent GLUT4 in the gastrocnemius muscle. 
Cross-sections (7 µm) from frozen and Tissue Tek® embedded gastrocnemius muscles 
were fixed in ice-cold acetone for 10 minutes. After drying, sections were incubated in 5 % 
BSA/TBS for 1 h at room temperature to block non-specific binding. Sections were 
incubated with anti-GLUT4 antibody (ab 654-250, abcam, Cambridge, United Kingdom) at 
a dilution of 1:400 in 1 % BSA/TBS for 2 h at room temperature. After washing with TBS, 
the sections were incubated with the CY3 conjugated secondary antibody (111-165-144, 
Jackson ImmunoResearch, USA) which was diluted 1:1000 in TBS for 1 h at room 
temperature. The sections were subsequently washed (4-times) and counterstained with 
DAPI (D9542, Sigma-Aldrich, Germany) at a dilution of 1:600 in TBS for 10 min at room 
temperature. GLUT4 detection was conducted under an inverse microscope (Axiovert200, 
Zeiss, Germany) with the appropriate filters for fluorescence of CY3 (red) and DAPI (blue) 
and the corresponding software AxioVision Rel. 4.6.3. 
 
Immunohistochemical staining and determination of soleus muscle fiber areas 
Cross-section, fixation, and blocking of non-specific binding were performed as described 
above for the gastrocnemius muscle. Soleus sections were incubated with anti-Laminin 
antibody (L9393, Sigma-Aldrich, Germany) at a dilution of 1:400 in 1 % BSA/TBS 
overnight at 4 °C. Afterwards the sections were incubated first with the corresponding 
secondary antibody (E0432, Dako, Denmark) and after that with the Streptavidin-
biotinylated horseradish peroxidase complex (RPN1051V, GE Healthcare, Germany) each 
1:400 diluted in TBS for 1 h at room temperature. To visualize the antigen-antibody 
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complexes 3,3´-Diaminobenzidine-tetrahydrochloride (DAB, Sigma-Aldrich, Germany) as 
substrate was used. Between the individual incubation steps sections were washed 
several times with TBS. Muscle fiber areas were measured with an inverse microscope 
(Axiovert200, Zeiss, Germany) and the corresponding software AxioVision Rel. 4.6.3. 
 
Statistical analysis  
Statistical significance of differences was calculated using Kruskal-Wallis one-way 
analysis of variance with a following Mann-Whitney U-test (SPSS Statistical Analysis 
System, Version 20.0). Statistical significance was established at p ≤ 0.05. 
 
 
Results 
 
Uterine wet weight, food intake and body weight 
To ascertain the estrogenic response of the experimental treatment and adequate 
delivery of compounds via osmotic mini pumps or enriched food, the uterine wet weights 
of all animals as the most reliable biomarker for estrogenic activity were measured 
(Owens and Ashby 2002) (Fig. 15). Only treatment with E2 or Alpha prevented the uterine 
atrophy in OVX rats, whereas administration of Beta and Gen had no effect. These results 
are in line with previous studies that have shown that only ER alpha mediates the 
stimulatory effect of E2 on the uterine wet weight (Hertrampf et al., 2007; Hertrampf et al., 
2008a; Hillisch et al., 2004; Weigt et al., 2012) 
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Fig. 15. Effects of E2, ER subtype-selective agonists and Gen on uterine wet weights after 17 
weeks of treatment. 
SHAM = sham-operated, OVX = ovariectomized, E2 = treated with 17beta-estradiol, Alpha = 
treated with ER alpha-selective agonist, Beta = treated with ER beta-selective agonist, Gen = 
treated with Genistein. Data shown are means ± SD. Mean values were significantly different for 
the following comparisons: *** vs. OVX (p≤0.001)  
 
 
 
 
Throughout the experimental period, OVX rats revealed significantly higher food 
consumption than the SHAM-treated animals. The OVX effect was antagonized by 
administration of E2 and Alpha, but not by Beta or Gen (Fig. 16C). 
The different feeding behavior of the animals was reflected by the body weight gain 
during the treatment period (Fig. 16B) and at the end of the experiment (Fig. 16A). All 
animal groups were obese at this time point, but the SHAM-, E2-, and Alpha-treated 
animals displayed significantly lower body weights than the untreated OVX animals. 
Substitution of OVX animals with Beta and Gen resulted in a body weight comparable to 
untreated OVX rats. 
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Fig. 16. Effects of E2, ER subtype-selective agonists and Gen on (A) body weight after 17 weeks 
of treatment, (B) course of body weight between week 0 and 15, and (C) weekly diet intake 
throughout the experimental period. 
SHAM = sham-operated, OVX = ovariectomized, E2 = treated with 17beta-estradiol, Alpha = 
treated with ER alpha-selective agonist, Beta = treated with ER beta-selective agonist, Gen = 
treated with Genistein. Data shown in A and C are depicted as minimum, 25th, 50th (median), 75th 
percentile and maximum of the distribution, empty circles dispay outliers. Data shown in B are 
means at the respective time points. Statistical significance for A and C was established as follows: 
*p≤0.05, **p≤0.01, ***p≤0.001 vs OVX. 
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Intra-peritoneal glucose tolerance test 
After an over-night fast, at time-point 0, the untreated OVX animal group displayed the 
highest blood glucose levels. Significantly lower levels were measured in the SHAM- and 
E2-treated animals, whereas the Alpha-, Beta -and Gen-substituted rats showed at least 
the same tendency (Fig. 17). 15, 30, 60, and 120 minutes after a bolus of 1 g/kg b.w. 
glucose was given intraperitoneally the glucose concentration were determined. 
Compared with untreated OVX animals the treatment with E2 led to significantly lower 
glucose concentrations at all time-points. The SHAM, Alpha, and Beta treated animals 
revealed significantly lower glucose levels after 30 and 60 min relative to untreated OVX 
rats, whereas substitution with Gen lowered the glucose level at time point 60 and 120 
min markedly. The slower glucose clearance in the untreated OVX rats was also reflected 
by the area under the plasma concentration/time curve (Fig. 18). 
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Fig. 17. Effects of E2, ER subtype-selective agonists and Gen on fasting blood glucose. 
SHAM = sham-operated, OVX = ovariectomized, E2 = treated with 17beta-estradiol, Alpha = 
treated with ER alpha-selective agonist, Beta = treated with ER beta-selective agonist, Gen = 
treated with Genistein. Data are depicted as minimum, 25th, 50th (median), 75th percentile and 
maximum of the distribution. Statistical significance was established as follows: **p≤0.01 vs OVX. 
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Fig. 18. Effects of E2, ER subtype-selective agonists and Gen on intraperitoneal glucose tolerance 
test (ipGTT). 
A: comparison of SHAM and OVX, B: comparison of OVX+E2 and OVX, C: comparison of 
OVX+Alpha and OVX, D: comparison of OVX+Beta and OVX, E: comparison of OVX+Gen and 
OVX, F: measurement of AUC (area under the curve). 
SHAM = sham-operated, OVX = ovariectomized, E2 = treated with 17beta-estradiol, Alpha = 
treated with ER alpha-selective agonist, Beta = treated with ER beta-selective agonist, Gen = 
treated with Genistein. Data shown in A–E are means ± SD. Data shown in F are depicted as 
minimum, 25th, 50th (median), 75th percentile and maximum of the distribution. Statistical 
significance was established as follows: *p≤0.05, **p≤0.01 vs OVX. 
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Stable isotope ratio analysis in liver, skeletal muscle, and adipose tissue 
To measure the glucose uptake in different tissues of the animals, the IRMS-analysis was 
used. In liver cells, the δ13C values in the untreated OVX animals were decreased relative 
to SHAM, E2- and Alpha-treated animals. Similar results were analyzed in both the soleus 
and the gastrocnemius muscle and the white adipose tissue displayed at least the same 
tendency (Fig. 19). Because of a pilot study, the impact of Beta and Gen treatment on 
glucose uptake was not determined.  
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Fig. 19. Effects of E2 and Alpha on glucose uptake in liver (A), adipose tissue (B), gastrocnemius 
muscle (C), and soleus muscle (D). 
SHAM = sham-operated, OVX = ovariectomized, E2 = treated with 17beta-estradiol, Alpha = 
treated with ER alpha-selective agonist, blank = animals without glucose application, intervention = 
animals received an oral application of 
13
C labeled glucose 3.5 hours before decapitation. Data 
shown are means ± SD. Each measuring point represents two animals analyzed in duplicate. 
Statistical significance was not established. 
 
 
 
GLUT4 expression in the gastrocnemius muscle 
Gastrocnemius muscles from animals that received glucose for IRMS-Analysis 3.5 h 
before decapitation were also evaluated for distribution of the insulin-dependent GLUT4 
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by immunohistochemical staining. The presence of GLUT4 in the cell membrane of 
SHAM-, E2-, and Alpha-treated animals was substantially higher than in untreated OVX 
animals (Fig. 20A–D).  
Real-time RT-PCR experiments, performed in all animals, revealed that the mRNA 
level of GLUT4 was lowest in untreated OVX rats. Significantly increased to OVX was the 
gene expression in Alpha- and Gen-treated animals, whereas the higher mRNA 
expression in SHAM-, E2-, and Beta-treated animals did not reach significance (Fig. 20E) 
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Fig. 20. (A-D) Effects of E2 and Alpha treatment on the GLUT4 expression and distribution in the 
gastrocnemius muscle. (E) Effects of treatment with E2, ER subtype-selective agonists and Gen on 
GLUT4 mRNA expression in the gastrocnemius muscle. 
GLUT4 was stained with Cy3 (red) and nuclei with DAPI (blue). A: SHAM, B: OVX, C: OVX+E2, D: 
OVX+Alpha. SHAM = sham-operated, OVX = ovariectomized, E2 = treated with 17beta-estradiol, 
Alpha = treated with ER alpha-selective agonist, Beta = treated with ER beta-selective agonist, 
Gen = treated with Genistein. mRNA expression data are means ± SD. *p≤0.05 vs OVX. 
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Cross-sectional fiber areas of the soleus muscle 
Recently, the ability of ER beta to increase the skeletal muscle mass in a rat model of 
nutrition-induced obesity was demonstrated (Weigt et al., 2012). To assess whether ER 
beta activation modulates skeletal muscle mass in leptin resistant ZDF rats the soleus 
muscle fiber areas in histological sections were measured. Treatment of OVX rats with 
estrogenic compounds led to significantly larger muscle fiber areas compared to untreated 
OVX HF animals, whereby muscle fiber sizes were largest in Beta- and Gen-treated 
animals (Fig. 21). 
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Fig. 21. Effects of E2, ER subtype-selective agonists and Gen on soleus muscle fiber sizes. 
SHAM = sham-operated, OVX = ovariectomized, E2 = treated with 17beta-estradiol, Alpha = 
treated with ER alpha-selective agonist, Beta = treated with ER beta-selective agonist, Gen = 
treated with Genistein. Data shown are means ± SD. *p≤0.05, **p≤0.01 vs. OVX. 
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Discussion 
 
In the present study, it was investigated how estrogens modulate glucose metabolism in 
leptin resistant female ZDF rats. Those animals were treated with E2, or, to achieve 
deeper knowledge which ER subtype is involved, with ER subtype-selective agonists 
Alpha or Beta for 17 weeks. In addition, a subset of OVX animals received a diet enriched 
with Gen to evaluate whether this phytoestrogen is able to induce effects similar to those 
of estrogens. 
 
The major finding in this study is that estrogens ameliorate disturbed glucose homeostasis 
via both ER subtypes. 
 
Uterine wet weight and body weight gain 
After 17 weeks of treatment uterine wet weight (Fig. 15) and body weight gain (Fig. 16A 
and B) in the animals were as expected and are in line with previous results. Only the ER 
alpha is responsible for the uterine growth response and the lower body weight gain 
compared to untreated OVX rats (Hertrampf et al., 2007; Hertrampf et al., 2008a; 
Hertrampf et al., 2008b; Hillisch et al., 2004; Weigt et al., 2012). These results confirm 
further the adequate delivery of all estrogenic compounds and the selectivity of the ER 
subtype-selective agonists. 
 
Food intake 
Although all animals were hyperphagic, ovariectomy led to a significantly higher food 
intake compared to SHAM animals. This OVX-induced effect was only antagonized by 
treatment with E2 and Alpha, but not by substitution with Beta or Gen (Fig. 16C). In 
previous results of our group this finding was only shown in tendency, where differences 
in food intake between untreated and with estrogenic compounds treated OVX animals or 
intact animals never reached significance (Hertrampf et al., 2006a; Hertrampf et al., 2007; 
Weigt et al., 2012; Zoth et al., 2010). Apart from our work, several research papers 
revealed a significant higher food intake in OVX animals compared to intact animals. 
However, this was often observed in short-term experiments (Ainslie et al., 2001; Chen 
and Heiman, 2001; Latour et al., 2001; Silva et al., 2010). In the present study, leptin 
resistance of the used rat strain might explain the more pronounced effect of E2- and 
Alpha-induced food intake reduction.  
Leptin is mainly produced by adipocytes and plays a key role in regulating feeding 
behavior and energy homeostasis. Circulating leptin crosses the blood-brain barrier and 
binds to its receptor in the hypothalamus (Friedman, 2002; Maffei et al., 1995). The 
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hypothalamus contains a number of small, interconnected nuclei such as the arcuate 
nucleus, ventromedial nucleus, paraventricular nucleus, lateral hypothalamic area, and 
dorsomedial nucleus. All of them express the leptin receptor and are implicated in the 
regulation of feeding behavior and energy expenditure (Simpson et al., 2009). Especially 
in the arcuate nucleus the catabolic effect of leptin by inducing the anorexigenic neurons 
POMC and CART and inhibiting the orexigenic neurons AgRP and NPY resulting in 
decreased food consumption and increased energy expenditure is well described (Barsh 
and Schwartz, 2002; Morton et al., 2006; Simpson et al., 2009). 
Both ER subtypes are expressed in the hypothalamus (Weiser et al., 2008) and 
literature data indicate that also estrogens interact with the neurobiological control of 
feeding behavior. For example, in cycling female rats the lowest food intake can be 
observed when the estrogen concentration is greatest (Blaustein and Wade, 1976; Butera, 
2010; ter Haar, 1972). Similar results were described for other mammals including guinea 
pig (Czaja et al., 1983; Czaja and Goy, 1975), sheep (Tarttelin, 1968), rhesus monkey 
(Czaja, 1975; Czaja and Goy, 1975), and the human females (Buffenstein et al., 1995). 
However, to what extend the both ER subtypes are involved in estrogenic modulation of 
eating behavior is still unclear. Administration of E2 into the ventromedial nucleus (that 
exclusively express the ER alpha (Weiser et al., 2008)), and into the paraventricular 
nucleus (described to express only the ER beta (Weiser et al., 2008)) have shown to 
decrease food intake in female rats (Bonavera et al., 1994; Butera and Beikirch, 1989; 
Palmer and Gray, 1986; Wade and Zucker, 1970). Further, in the arcuate nucleus (where 
both ER subtypes are expressed) estrogen deficiency stimulated the expression of NPY 
mRNA, while the expression of POMC mRNA was decreased (Pelletier et al., 2007). 
Taken together, this study with leptin resistant ZDF rats shows that the E2-induced lower 
food intake is mediated via the ER alpha and seems to be independent of leptin signaling. 
 
Systemic glucose tolerance 
The hypothesis that ovariectomy of ZDF rats results in impaired glucose tolerance when 
compared to intact or E2-substituted animals has been confirmed. A significantly lower 
fasting glucose was found in SHAM and E2-treated animals compared to untreated OVX 
animals. Administration of Alpha, Beta, and Gen showed a similar tendency (Fig. 17). 
Regarding the ipGTT, all animal groups that were intact or received estrogenic 
compounds, tolerated the glucose load better than untreated OVX animals (as 
demonstrated by lower AUCs in Fig. 18), whereby the strongest effect was shown in E2-
treated rats. However, the high glucose levels that are described for obese male ZDF rats 
were not reached. Apparently, the lower estrogen levels in males cannot be solely 
responsible for gender dimorphism of glucose homeostasis in ZDF rats.  
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Glucose homeostasis in liver, adipose tissue, and skeletal muscle 
IRMS was used to elucidate the glucose uptake in metabolic relevant tissues further (in 
SHAM, OVX, OVX+E2, and OVX+Alpha animals). 3.5 h after an oral glucose load the 
fasted uptake was measured in liver (Fig. 19A): here, in SHAM, E2-, and Alpha-
substituted animals the amount of absorbed glucose was substantially higher than in 
untreated animals. A similar pattern was observed in skeletal muscle (gastrocnemius and 
soleus) and adipose tissue, although the effect was weak in adipocytes (Fig. 19B–D). 
Thus, the IRMS results reflect the systemic glucose tolerance in the animals (at least in 
the SHAM, OVX, OVX+E2, and OVX+Alpha animals).  
Clearance of high blood glucose levels is mostly promoted by insulin. In liver insulin 
regulates glucose metabolism by decreasing gluconeogenesis and inducing glycogenesis. 
In skeletal muscle (the major site of whole body glucose disposal) and white adipose 
tissue (the major site of energy storage) insulin initiates the translocation of vesicles 
containing GLUT4 to the plasma membrane, enabling the uptake of glucose (Gould and 
Holman, 1993; Magkos et al., 2010).  
The metabolic role of ER alpha was investigated in several studies and is better 
understood than the impact of ER beta.  
In liver, ER alpha deficiency was described to result in hepatic insulin resistance 
compared to wild types, mainly attributed to ineffective suppression of endogenous 
glucose production. Further, αERKO mice displayed increased hepatic lipogenesis 
compared to wild type mice, an additional indication of impaired insulin sensitivity due to 
enhanced lipid accumulation within the liver. βERKO mice were not investigated regarding 
hepatic insulin resistance and lipid accumulation in this study (Bryzgalova et al., 2006).  
In skeletal muscle, the ER alpha was shown to increase GLUT4 expression, while the 
ER beta mediated its repression (Barros et al., 2009; Barros et al., 2006). The present 
study confirmed this effect of ER alpha in the gastrocnemius muscle, because GLUT4 
mRNA expression was highest in Alpha-treated animal groups (Fig. 20E). A similar 
pattern was observed by treatment with Gen (effects of Gen will be discussed at the end 
of the discussion part). Further, the translocation of insulin-dependent GLUT4 in Alpha-
treated OVX rats was similar to E2-substituted and SHAM animals and more effective 
than in untreated OVX rats (Fig. 20A–D and only analyzed in the animals that received a 
glucose load at the day of section).  
The impact of both ER subtypes on glucose metabolism in adipose tissue is less clear 
but also here the ER alpha seems to increase GLUT 4 expression (Barros et al., 2009).  
Taken together, the ipGTT and the IRMS confirmed the anti-diabetic role of ER alpha 
in leptin resistant ZDF rats. Unfortunately, IRMS data for Beta- or Gen-treated animals 
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cannot be provided, but the ipGTT of these both groups displayed a similar improved 
glucose tolerance like Alpha-treated animals (Fig. 18).  
The ipGTT data in Beta-treated animals may be explained by the anabolic effect of 
ER beta that was previously demonstrated: activation of ER beta stimulated the muscle 
growth in a classical Hershberger assay, accelerated the regeneration of injured skeletal 
muscles and caused larger soleus muscle fiber areas in rats (Velders et al., 2012; Weigt 
et al., 2012). These findings are in line with the soleus muscle fiber sizes presented in this 
study, where the Beta-substituted OVX ZDF rats again displayed the largest cross-
sectioned fiber areas in the soleus muscle (Fig. 21). This observation in Beta-treated rats 
might compensate the decreased GLUT4 expression, which was described for ER alpha 
deficient mice (Bryzgalova et al., 2006) and measured on gene expression level in this 
study. However, the increased muscle mass and the fact that the slow-twitch fiber type 
soleus generates energy predominantly by means of oxidative metabolism it can be 
hypothesized that at least Beta-treated animals possess an enhanced utilization of 
glucose, which results in an improved glucose tolerance.  
The strongest effect regarding improved systemic glucose tolerance was observed in 
E2-treated animals and might be explained through activation of both signaling pathways. 
 
Genistein 
The isoflavone Gen in this study was given orally in a range from 55 to 30 mg/kg/day 
(changes in intake must be attribute to body weight gain during the experimental period, 
observed in all animal groups). Such a dosis is relatively high – an human equivalent 
dosage (Reagan-Shaw et al., 2008) can only be reached by dietary supplements using a 
dose, which is three to four times higher than the maximum dose commonly used for 
postmenopausal treatment (Andres and Lampen, 2012; Hooper et al., 2010; Messina and 
Wood, 2008; Steinberg et al., 2011; Wei et al., 2012). Treatment with Gen showed 
significant effects in skeletal muscle as follows. Compared to untreated OVX ZDF rats, 
Gen-treated animals revealed significantly larger soleus muscle fiber areas similar to that 
of Beta-treated animals (Fig. 21). However, Gen-treated rats also showed increased 
GLUT4 mRNA expression in the gastrocnemius muscle similar to Alpha-treated animals 
(Fig. 20E). Consequently, the systemic glucose tolerance in animals that were treated with 
Gen was improved compared to untreated OVX rats and similar to SHAM and substituted 
animals (Fig. 18). The ability of Gen to activate ER beta-selective mechanisms such as 
anabolic effects was already shown in a recent publication of our group: Gen activates 
anabolic mechanisms in the skeletal muscle similar to Beta (Velders et al., 2012). 
However, in contrast to Alpha and Beta – at the given doses – Gen binds to both 
receptors even. Therefore, it can be speculated that Gen-treated animals may improve 
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their glucose homeostasis through enhanced expression of GLUT4 as well as larger 
muscle fibers in skeletal muscle. 
 
Conclusion 
 
In summary, the results provide evidence that ER alpha affects the feeding behavior of 
female ZDF rats independent of leptin signaling. Substitution of OVX rats with E2, ER 
subtype-selective agonists Alpha and Beta, and Gen improved systemic glucose tolerance 
compared to untreated OVX rats. This result correlates to the accelerated glucose uptake 
in liver, adipocytes, and skeletal muscle in the appropriate animal groups (only measured 
in SHAM, OVX, E2, and Alpha-treated animals). In skeletal muscle, the ER alpha 
ameliorated glucose homeostasis through an increased expression of GLUT4 and 
translocation to the cell membrane. By contrast, the ER beta enlarges the muscle fibers 
that may result in enhanced glucose utilization. The isoflavone Gen showed an increased 
GLUT4 expression level (similar to Alpha) as well as larger soleus muscle fiber areas 
(similar to Beta). Therefore, Gen seems to affect both pathways (when provided in the 
form and dose used in this study). Taken together, ER alpha accelerated the glucose 
absorbance in liver and adipose tissue and decreased food intake. Activating either ER 
subtype improved the glucose metabolism in female ZDF rats, but at least in the skeletal 
muscle via two different molecular pathways.  
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In this final chapter, the key findings of the thesis are represented which subsequently will 
be discussed and compared with the current literature. Against this background, a 
conclusion and outlook are given finally. 
 
As the main sex hormones in women, estrogens are essential for menstrual cycle control, 
reproduction, and development of female secondary sexual characteristics. Also in men, 
balanced levels of estrogens contribute to male fertility and a healthy libido. Beside their 
important function on the reproductive system, estrogens play an important regulatory role 
on the cardiovascular, immune, excretory, and central nervous system as well as in 
metabolic processes (Heldring et al., 2007). This far-reaching influence of estrogens on 
the whole body becomes obvious in pathophysiological conditions when estrogen 
production is disturbed as well as after menopause when the primary function of the 
ovaries has ceased. In both cases, of those affected have a higher risk of developing 
numerous diseases, e.g., cardiovascular disease, neurogenerative diseases, various 
types of cancer (breast, endometrium, colon, prostate), osteoporosis, and obesity (Deroo 
and Korach, 2006; Louet et al., 2004; Rolland et al., 2007; Toth et al., 2000b). Obesity is 
the result of a chronic imbalance of energy homeostasis, meaning that intake of energy 
continuously exceeds its expenditure. Particularly, due to the rapidly increasing 
prevalence of obesity and co-morbidities, the impact of estrogens on processes related to 
energy homeostasis became the research focus in the last years. Estrogens act through 
activation of two distinct ER subtypes, ER alpha and ER beta (Enmark and Gustafsson, 
1999; Heldring et al., 2007; Nilsson et al., 2001). Since both receptors could serve as the 
basis for therapeutic interventions it is of great interest to discriminate between 
physiological processes regulated through ER alpha, ER beta or both. Substances that 
may play a role in therapy of estrogen-associated diseases could be of synthetic origin 
(SERMS) but also plant-derived (phytoestrogens). Here, the isoflavone genistein, which 
can activate both ER subtypes, are under intensive investigation. 
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Key findings of the presented work 
 
The aim of the present work was to obtain more detailed insights into the action of E2 on 
energy intake, body weight, and metabolism of glucose and lipids in adipose tissue, liver, 
and skeletal muscle by means of animal experiments. Special emphasis was given to the 
effects of the two ER subtype-selective agonists Alpha (16alpha-LE2) and Beta (8beta-
VE2) and the isoflavone genistein.  
 
The major finding was:  
 The ER beta-selective agonist results in an enhanced utilization of glucose and 
lipids by anabolic activity. 
 
Other key findings were as follows: 
 Activation of ER alpha affects feeding behavior in ZDF rats – an effect that might 
be relevant in leptin resistant individuals. 
 Estradiol reduces body weight gain via the stimulation of ER alpha. 
 Estradiol decreases lipogenesis via either ER subtype-selective agonist in adipose 
tissue, liver, and skeletal muscle. 
 Estradiol improves glucose tolerance and insulin sensitivity via either ER subtype – 
at least in the skeletal muscle by two different molecular pathways. 
 Genistein exert effects on energy homeostasis similar to those of the ER beta-
selective agonist. 
 
 
ER beta signaling results in an enhanced utilization of glucose and lipids by 
anabolic activity 
 
Menopause is characterized by an increase of adipose tissue and a loss of muscle mass, 
resulting in a significant change of the body composition. In average, postmenopausal 
women have 20% more fat than premenopausal women (Ley et al., 1992). Further, 
studies have shown a muscle mass decline of 0.6% per year after menopause (Rolland et 
al., 2007).  
In postmenopausal women, redistribution of fat pads can be observed as follows: the 
“gynoid” fat distribution pattern, which is typical for premenopausal women and 
characterized by fat accumulation around the hips and thighs, becomes similar to that in 
men (also referred to as “android” fat distribution pattern). In men, fat is mainly 
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accumulated around the trunk and upper body such as the abdomen, chest, neck and 
shoulder (Ley et al., 1992). Epidemiologic studies correlate the “android” fat pattern with 
an increased risk to develop cardiovascular disease and insulin resistance (Anghel et al., 
2007). 
In light of the above-mentioned findings, the anabolic potency of the ER beta-selective 
agonist that was observed in the presented work may be highly relevant. Rats treated with 
E2 and the ER beta-selective agonist showed a significant modulation of soleus muscle 
genes involved in muscle growth, repair and maintenance (Pax7 and Igf1) compared to 
untreated OVX animals (chapter two). Further, treatment with the ER beta-selective 
agonist resulted in the largest soleus muscle fibers in Wistar rats with nutrition-induced 
obesity (chapter two) as well as in obese leptin resistant ZDF rats (chapter four).  
This specific role of ER beta in skeletal muscle homeostasis was previously shown in 
a model of toxin-induced skeletal muscle damage. Here, ER beta signaling accelerated 
the regeneration of injured skeletal muscles in female Wistar rats, whereas ER beta 
depletion in ERKO mice resulted in a reduced ability. Anabolic potency of the ER beta-
selective agonist was also shown in a classical Hershberger assay with healthy male 
Wistar rats (Velders et al., 2012).  
Thus, the ER beta seems to have the potency to increase skeletal muscle mass that 
in turn improves muscle/fat ratio of the body, and enhances skeletal muscle uptake and 
utilization of fuels. This important observation might explain the improved lipid and 
glucose metabolism in animals treated with the ER beta-selective agonist compared to 
untreated animals, which will be discussed in detail below.  
 
 
Activation of ER alpha affects feeding behavior in ZDF rats – an effect that 
might be relevant in leptin resistant individuals 
 
Increased daily food consumption with insufficient energy expenditure is considered as 
the main cause for the development of obesity. In the relevant literature, the influence of 
estrogens on central regulation of energy balance is still a matter of debate.  
My studies indicate that in a long-term experiment of nutrition-induced obese female 
Wistar rats neither E2 nor other ER ligands had a significant effect of energy intake 
(chapter two). The higher food intake that was observed in animals on LF diet had to be 
attributed to its lower energy content compared to the HF diet (chapter two). This result is 
in line with previous findings from our laboratory (Hertrampf et al., 2006a; Hertrampf et al., 
2007). In contrast, E2 treatment in leptin resistant female obese ZDF rats decreased 
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weekly energy intake markedly throughout the experimental period; an effect that was 
mediated via the ER alpha (chapter four).  
In the literature, there are animal studies showing that ovariectomy increases daily 
food consumption. This effect was often described in short-term experiments (Ainslie et 
al., 2001; Chen and Heiman, 2001; Latour et al., 2001; Roesch, 2006; Saengsirisuwan et 
al., 2009; Santollo et al., 2007; Silva et al., 2010) and related to activation of ER alpha 
(Roesch, 2006; Santollo et al., 2007). Studies in αERKO rodents provided also different 
results: deletion of ER alpha showed both an increase of daily food consumption (Geary 
et al., 2001; Musatov et al., 2007; Naaz et al., 2002) and no effect on this parameter 
(Faulds et al., 2012; Heine et al., 2000). 
Leptin is the most important protein that regulates energy intake and expenditure by 
acting on several neurons on the hypothalamus. Some of these neuronal subsets, which 
are involved in leptin signaling, have also been described to express the ER alpha 
(ventromedial nucleus), the ER beta (paraventicular nucleus) or both ER subtypes 
(arcuate nucleus). Several animal studies were carried out to elucidate the action of E2 in 
the central nervous system, but the outcomes were somewhat controversial. Both 
administration of E2 in the paraventricular nucleus (Bonavera et al., 1994; Palmer and 
Gray, 1986) and in the ventromedial nucleus (Jankowiak and Stern, 1974; Wade and 
Zucker, 1970) have shown to reduce food intake in OVX rats, indicating that both ER 
subtypes may be involved in eating behavior. A further study in OVX female rats utilizing 
intracerebroventricular infusions of E2 alone or in combination with antisense 
oligodeoxynucleotides for both ER subtypes postulated that the ER beta is responsible for 
the anorectic action of E2 (Liang et al., 2002).  
Taken together, my studies indicate that activation of ER alpha has the potency to 
attenuate daily energy intake. However, this effect only becomes an issue when 
individuals are resistant to leptin. Whether and to what extent the ER beta may play a role 
in energy consumption remains to be clarified. 
 
 
Estradiol reduces body weight gain via the stimulation of ER alpha 
 
Obesity is defined as excessive fat enrichment with a BMI greater than 30 kg/m2 in adults. 
Therefore, increased body weight is an initial predictor for generation of obesity. All animal 
experiments that were carried out in the presented work demonstrated a significantly 
lower body weight gain by treatment with E2 (chapter two and four) and the ER alpha 
selective agonist (chapter two and four) when compared to untreated OVX animals. These 
data agree with data from the literature (Roesch, 2006; Saengsirisuwan et al., 2009; 
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Santollo et al., 2007; Wegorzewska et al., 2008) and with previous results from our group 
(Hertrampf et al., 2007; Hertrampf et al., 2008a; Hertrampf et al., 2008b). To my 
knowledge, only one study in OVX rats showed a decreased body weight gain by 
activation of ER beta – an effect resulting from decreased food intake by the rats 
compared to OVX animals (Liang et al., 2002). Body weight data from ERKO mice are 
more controversial. Increased body weight was shown in αERKO mice (Bryzgalova et al., 
2006; Geary et al., 2001; Musatov et al., 2007; Naaz et al., 2002), but also in βERKO mice 
(Foryst-Ludwig et al., 2008; Seidlova-Wuttke et al., 2012) when compared to wild type 
counterparts.  
To date the cause of body weight gain following estrogen deficiency is not exactly 
known. Multiple factors may contribute to the E2-induced reduced rate of body weight gain 
including both central and peripheral effects. As mentioned above, the attenuated daily 
food intake mediated via ER alpha was discussed in animal models of E2 depletion (OVX) 
(Roesch, 2006; Santollo et al., 2007) and ERKO (Geary et al., 2001; Musatov et al., 2007; 
Naaz et al., 2002) as one important reason for the higher body weight gain. Further, 
decreased energy expenditure shown in αERKO mice compared to wild types was also 
discussed to cause increased body weight in these animals (Heine et al., 2000; Musatov 
et al., 2007). The latter observation is in line with a previous study in our laboratory. Here, 
ovariectomy of Wistar rats significantly decreased their movement drive compared to 
SHAM animals – an effect that was antagonized by treatment with E2 and Alpha but not 
by application of Beta (Hertrampf et al., 2007). Moreover, an older study using intact 
female rats showed that energy expenditure of rats is highest during proestrus when 
circulating levels of estrogens are highest (Anantharaman-Barr and Decombaz, 1987). 
In light of the specific role of ER beta on skeletal muscle, a further explanation for the 
increased body weight in Beta-treated animals could be an altered body composition. In 
Beta-treated Wistar rats, visceral fat content and related parameters (adipocyte size, 
leptin levels, lipo-/adipogenesis) were lower than in OVX animals and similar to Alpha- 
and E2-treated animals. In contrast, the complete body weight of Beta-treated animals 
was comparable to OVX rats.  
Taken together, the conducted studies demonstrate that activation of ER alpha is 
responsible for the reduced body weight gain in E2-treated rats. Increased movement 
drive by activation of ER alpha seems to be an important factor for this observation, while 
feeding behaviour does not appear to be essential. Based on the observed anabolic 
potency of ER beta the increased body weight by activation of ER beta might indicate that 
in these animals the body composition has changed. 
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Estradiol decreases lipogenesis via either ER subtype-selective agonist in 
adipose tissue, liver, and skeletal muscle 
 
Obesity is characterized by excessive fat enrichment in the abdominal cavity. Moreover, 
an excess supply of fuel molecules leads to increased lipogenesis and further to fat 
accumulation in non-adipose tissues like liver and muscle. Hence, such affected tissues 
are implicated in an impaired insulin signaling (Anghel and Wahli, 2007). The liver is the 
key organ in composition of blood lipids. Here, FFA (de novo-synthesized or delivered by 
food) are processed to triglycerides that are then incorporated into VLDL for transport via 
blood to adipose tissue (storage) or muscle (energy production). A dyslipidemic profile in 
the blood is one important risk factor to develop cardiovascular diseases and is often 
associated with obesity, impaired insulin sensitivity but the loss of ovarian function also 
comes into play (Baxter et al., 2003; Chan and Woo, 2010; van Beek et al., 1999). 
 
Influence on adipose tissue 
The work presented here demonstrated that E2 treatment of obese Wistar rats results in 
lower visceral fat content, smaller adipose cells, and reduced circulating leptin levels 
compared to untreated OVX animals. Further, this effect was mediated via either ER 
subtype-selective agonist (chapter two). This was in line with the observation that both ER 
subtype-selective agonists decreased adipose mRNA levels of several genes that are 
involved in lipogenesis (SREBP1c and FAS) and adipogenesis (LPL and PPAR gamma) 
(chapter three).  
The anti-lipogenic effect of E2 on adipose cells was described before by different 
authors (Bryzgalova et al., 2008; Cooke and Naaz, 2004; D'Eon et al., 2005; Rogers et al., 
2009; Saengsirisuwan et al., 2009). Only few studies were conducted to evaluate whether 
these actions are mediated through ER alpha, ER beta or both receptors and the results 
from these studies are still controversially discussed. The key role on fat homeostasis is 
attributed to the action of ER alpha, because this ER subtype was shown to reduce the 
accumulation of triglycerides, expression of LPL, and adipose tissue mass (Bryzgalova et 
al., 2006; Heine et al., 2000; Homma et al., 2000). However, the impact of ER beta was 
not investigated in these studies. Another study using only βERKO mice revealed an anti-
lipogenic action of ER beta through a negative cross talk with PPAR gamma (Foryst-
Ludwig et al., 2008). In summary, these reports already indicate that both ER subtypes 
are involved in the anti-lipogenic action of estrogens in adipose tissue. This indication is 
supported by my studies: the observed effects are mediated by activation of either 
subtype. 
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Influence on liver and skeletal muscle 
In the rat model of nutrition-induced obesity, the anti-lipogenic action of E2 was also 
shown in liver and soleus muscle. Treatment with E2 and both ER subtype-selective 
agonists reduced both TG accumulation and mRNA levels of lipogenic genes (SREBP-1c 
and FAS). By contrast, mRNA expression of markers involved in fatty acid utilization and 
transport showed no significant differences between the experimental animal groups 
(chapter three).  
Similar to adipose tissue an E2-induced decrease of lipogenesis in liver and muscle was 
shown before (Bryzgalova et al., 2008; D'Eon et al., 2005; Gao et al., 2006) and related to 
activation of ER alpha (Bryzgalova et al., 2006). But again, the impact of ER beta was not 
investigated.  
 
Influence on blood lipids 
In obese Wistar rats ovariectomy resulted in significantly increased serum levels of TC 
and the lipoproteins HDL, LDL, and VLDL compared to SHAM. E2 treatment markedly 
reduced levels of TC and VLDL, whereas LDL levels were moderately decreased – an 
effect that was mediated by activation of ER alpha. HDL levels were not influenced by any 
treatment (chapter two). Thus, the LDL/HDL as well as (VLDL+LDL)/HDL ratios were 
more favourable with respect to the development of cardiovascular diseases in E2- and 
Alpha-treated animals. This observation confirms the relative cardiovascular protection of 
premenopausal women compared to women after menopause (Dubey et al., 2005; Ling et 
al., 2006). However, based on the supposed higher metabolic rate in Beta-treated animals 
the observed higher blood lipids could be an indication for enhanced transport of lipid 
molecules to the muscle for energy production. 
 
Taken together, in the study with obese Wistar rats highly selective agonists for both ER 
subtypes were used in one experiment. To my knowledge, this is the first report 
demonstrating that stimulation of either ER subtype participates in the anti-lipogenic 
properties of E2 in adipose, liver, and skeletal muscle. Moreover, at least in part the 
underlying molecular mechanisms are similar. However, an additive effect by treatment 
with E2 including activation of both ER subtypes was not observed. 
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Estradiol improves glucose tolerance and insulin sensitivity via either ER 
subtype – at least in the skeletal muscle by two different molecular pathways 
 
Insulin resistance is one obesity-associated risk factor and is characterized by an 
inadequate response of cells to the action of insulin. 
Wistar rats with nutrition-induced obesity were normoglycemic and did not show 
significant differences on fasting glucose and insulin levels after 10 weeks (chapter three). 
However, insulin levels were highest in untreated OVX animals compared to animals that 
received estrogenic compounds or intact rats (chapter three). The calculated HOMA-
Indices fit these data, indicating that untreated OVX animals need higher insulin levels for 
glucose disposal from the blood than the other groups. By contrast, ovariectomy 
increased hepatic rate of glucose uptake – an effect that was antagonized by treatment 
with E2 and Alpha but not by Beta and Gen. mRNA expression pattern of PPAR gamma 
(a marker for increased insulin sensitivity) correlated to hepatic glucose uptake, because 
highest mRNA level of PPAR gamma was found in untreated, Beta- and Gen-treated 
animals (chapter three). However, in light of increased TG accumulation in liver and 
muscle of untreated OVX animals at least in these animals the up-regulation of PPAR 
gamma mRNA could be an offset mechanism to improve insulin sensitivity. 
In obese leptin resistant ZDF rats, estrogen deficiency led to a more disturbed glucose 
homeostasis compared to Wistar rats with nutrition-induced obesity. In female ZDF rats, 
ovariectomy already resulted in significant higher fasting glucose levels compared to 
SHAM and E2-treated rats (chapter four). Activation of either ER subtype showed at least 
the same tendency. The results obtained from the performed ipGTT were more obvious: 
treatment with all estrogenic compounds improved glucose tolerance compared to 
untreated OVX rats. The strongest effect was observed in E2-treated animals that 
significantly better tolerated the glucose load at each time point compared to OVX. 
Moreover, increased glucose uptake was also measured in liver, adipose tissue, and 
skeletal muscle in SHAM, E2-, and Alpha-treated animals compared to OVX. Further 
investigations in the skeletal muscle indicated that stimulation of the two ER subtypes 
activates two distinct molecular pathways: GLUT4 expression and translocation to the cell 
membrane in the gastrocnemius muscle was most effective by treatment with Alpha, while 
Beta treatment led to the largest soleus muscle fiber sizes compared to OVX rats. 
In the literature, improved sensitivity towards glucose and insulin (systemic and of 
peripheral tissues) by E2 was shown in several studies using either animal models of 
ERKO or E2 replacement/application (Bryzgalova et al., 2008; Gao et al., 2006; Riant et 
al., 2009; Saengsirisuwan et al., 2009). This finding was related to activation of ER alpha 
(Barros et al., 2009; Barros et al., 2006; Bryzgalova et al., 2006; Heine et al., 2000; 
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Lundholm et al., 2008) Lundholm 2008, Barros 2006, 2009). Investigations with βERKO 
mice showed that the ER beta had either no effect (Bryzgalova et al., 2006) or an adverse 
impact (Barros et al., 2009; Foryst-Ludwig et al., 2008) on systemic glucose sensitivity 
compared to wild types. The pro-diabetogenic action of ER beta was described to result 
from decreased muscular GLUT4 expression and distribution (Barros et al., 2009; Barros 
et al., 2006) or a negative cross-talk with adipose PPAR gamma (Foryst-Ludwig et al., 
2008). The finding from Barros and colleagues fit to my results so far that the ER alpha is 
responsible for GLUT4 modulation. The described PPAR gamma effect by Foryst-Ludwig 
and colleagues was in my studies also mediated through ER alpha stimulation. 
Taken together, my studies demonstrate that either ER subtype improves glucose and 
insulin sensitivity. At least in the skeletal muscle, the underlying molecular pathways are 
different. Interestingly, systemic glucose tolerance was highest in E2-treated ZDF rats that 
might be an indication for an additive effect by activation of both pathways in skeletal 
muscle. 
 
 
Genistein exerts effects on energy homeostasis similar to those of the ER 
beta-selective agonist 
 
The influence of the isoflavone Gen on energy metabolism has been the focus of 
numerous studies. The results acquired regarding food intake, body weight, adipose 
tissue mass (reviewed in Orgaard and Jensen, 2008) and glucose metabolism (Behloul 
and Wu, 2013; Fu et al., 2010; Lee et al., 2009; Zhong et al., 2011) are very different. The 
reasons therefore are many variables, such as in vitro or in vivo studies, age and sexes of 
animals used, food composition, use of soy protein or isolated isoflavones, doses used 
and dosage form, individual intestinal microbiota, duration of the experimental period as 
well as differences in the applied methods. 
In my studies, Gen was given orally by enriched food that corresponds to the usual 
route of exposure. In both animal experiments, the daily Gen intake has changed during 
the experimental period due to body weight gain and differences in food intake of the 
animals. However, the dose used was relatively high and can only be reached by dietary 
supplements in humans (Reagan-Shaw et al., 2008). A human equivalent dose can be 
obtained using a daily dose, which is approximately two to four times higher than the 
maximum dose commonly used for postmenopausal treatment (Andres and Lampen, 
2012; Hooper et al., 2010; Mahady, 2005; Messina and Wood, 2008; Steinberg et al., 
2011; Wei et al., 2012). Gen and Gen-metabolites may act in a synergistic manner, 
CHAPTER FIVE 
 
 
 
95 
whereby their concentrations may differ dependeng on tissue type. In general, in my 
studies administration of Gen resulted in effects very similar to those that were observed 
by treatment with Beta. 
Comparable to Beta treatment, Gen administration to OVX animals showed no effect 
on uterine wet weight, energy intake, and body weight in both animal models compared to 
untreated OVX rats (chapter two and four). These observations confirm – at least in part – 
studies that used a similar dosage of genistein (Hertrampf et al., 2009b; Kim et al., 2006; 
Naaz et al., 2003; Penza et al., 2006).  
Compared to untreated OVX animals, in liver and muscle of nutrition-induced obese 
Wistar rats Gen and Beta treatment led to a similar reduction of hepatic and muscular 
lipogenesis and TG content. Further, muscular mRNA expression of Igf1 and Pax7 was 
modulated in a similar manner. No influence of Gen and Beta treatment was observed 
regarding hepatic and muscular PPAR gamma mRNA expression, glucose uptake in liver, 
and blood lipid profile. Contrary to Beta treatment no influence of Gen was measured on 
adipose tissue (visceral fat mass, adipocyte size, circulating leptin levels, and lipo-
/adipogenetic mRNA levels) when compared to untreated OVX rats (chapter two and 
three). 
Also in obese ZDF rats, administration of Gen showed very similar effects to Beta 
treatment regarding fasting glucose, ipGTT curve, and soleus muscle fibers (chapter four). 
Especially the ability of Gen to act in an ER beta-specific manner on skeletal muscle was 
shown before (Velders et al., 2012). 
The specific action of Gen on various tissues may depend on their ability to 
accumulate Gen or its metabolites. Such data are very limited, but there are reports 
showing that particularly endocrine-active tissues (thyroid gland, liver, brain, prostate, 
ovaries, uterus, and mammary gland) accumulate high levels of Gen, whereby its 
concentration often exceeds plasma levels (Chang et al., 2000; Hedlund et al., 2005). 
Interestingly, Gen concentration in livers of female Sprague-Dawley rats was 
approximately ten times higher than in male livers (Chang et al., 2000). This may explain 
the observed hepatic effects of Gen in my studies. To my knowledge, no data are 
available for Gen accumulation in adipose tissue and skeletal muscle so far.  
Gen’s preference to bind to ER beta was reported before by Kuiper and colleagues 
and my results confirm this observation (Kuiper et al., 1998). However, unlike to the ER 
subtype-selective agonist Gen can act via both ER subtypes. Gen’s preference for one of 
the two ER subtypes seems also to depend on their expression ratio in the respective 
tissue. This was shown in previous studies of our group (Hertrampf et al., 2007; Schleipen 
et al., 2011). Coexpresion of ER alpha and beta in skeletal muscle cells (Barros et al., 
2009) could explain the observed effects of Gen in the skeletal muscle of ZDF rats, where 
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Gen treatment seems to affect both pathways (GLUT4 expression via ER alpha and 
muscle fiber size via ER beta).  
Finally, Gen also modulates non-hormonal effects. Therefore, the here observed 
effects do not have to be exclusively mediated via ERs. 
Taken together, results obtained from this work indicate that Gen acts similarly to the 
ER beta-selective agonist (except on adipose tissue). Especially, the similar ability to 
induce anabolic activity in the soleus muscle might be highly relevant. A more effective 
utilization of fuels could explain the lower TG content in muscle and liver as well as 
improved glucose metabolism in the respective animals. Gen might offer an accessible 
and cheap treatment alternative to already existing therapies. In general, more research is 
warranted regarding tissue-specific accumulation and potential adverse effects of 
genistein such as cancer risk. With regard to my results, the effects of Gen observed in 
this work should be examined by using lower Gen doses (comparable to dietary 
supplements) to minimize potential adverse effects. 
 
 
Conclusion and outlook 
 
With the onset of menopause, the enourmous decline of endogenous estrogens results in 
far-reaching physiological changes that – in combination with physical inactivity – are the 
major reason for the development of obesity and co-morbidities. New strategies that focus 
on prevention and therapy of obesitiy in menopausal and postmenopausal women have to 
be found.  
My studies clearly demonstrate that estrogens decrease lipogenesis and increase 
insulin sensitivity via either ER subtype. Especially the observed anabolic potency of ER 
beta in the skeletal muscle, which seems to be the underlying molecular mechanism for 
improved glucose and lipid metabolism in such treated animals, might be of great 
importance. ER beta signaling is not involved in regulation of proliferation of uterus and 
mammary gland (described before by (Curtis Hewitt et al., 2000; Diel et al., 2004; 
Molzberger et al., 2011) and shown in my studies by uterine wet weights). Therefore, 
compounds that only activate ER beta might be an excellent strategy for prevention and 
therapy of obesity and co-morbidities in postmenopausal women without increasing the 
risk for estrogen-sensitive forms of cancer.  
Beside synthetic SERMs, the natural phytoestrogen Gen might be a further 
alternative, because Gen administration affects skeletal muscle homeostasis in a similar 
way to Beta treatment. Gen can activate both ERs and is already placed on the marked 
for treatment of postmenopausal complaints. Women, who suffer from climacteric 
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complaints, are recommended to replace hormones. HRT is based on the idea to treat 
such discomforts by supplementing estrogens and progestins. However, conventional 
HRT is strongly associated with a larger incidence of heart attacks, strokes, and breast 
cancer (most likely through overstimulation of proliferation by estrogens (Beral, 2003). 
Previous animal studies of our laboratory, and shown in the presented work, revealed that 
Gen, when given orally, does not, or only very weakly, induce uterus proliferation 
(Hertrampf et al., 2006b; Hertrampf et al., 2009a; Hertrampf et.al., 2009b). Therefore, Gen 
might be an excellent alternative – not only to the conventional HRT for treatment of 
climacteric complaints, but also as a strategy for prevention and therapy of obesity and 
co-morbidities. However, the role of Gen on the incidence of breast cancer in 
postmenopausal women – particularly in the Western world – is discussed controversially 
and needs further investigations (Andres and Lampen, 2012; Hertrampf et al., 2006b; 
Molzberger et al., 2012). 
Therefore, based on my studies I conclude that an effective way to treat obesity and 
co-morbidities in postmenopausal women might be substances that only activate ER beta. 
A combination with physical activity may support the therapy of obesity and co-
morbidities. For postmenopausal women suffering from climacteric complaints as well as 
obesity and co-morbidities, the isoflavone Gen might be a natural alternative. 
 
To verify my results more research is warranted. This includes both in vitro and in vivo 
experiments. In vitro studies enable a more detailed insight in the underlying molecular 
mechanisms of which molecular pathway either ER subtype-selective agonist influences 
metabolism. Further, the question whether the observed effects of estrogens are ER-
mediated can be addressed by using selective ER agonists and antagonists in 
combination. Animal studies using both ER subtype-selective agonists may offer deeper 
knowledge in the action of E2 and/or physical activity in liver, adipose tissue, brain, and 
skeletal muscle but also the endocrine pancreas. Foremost a combination of physical 
activity and Beta treatment and whether Gen might be used as an alternative should be 
investigated by using animal experiments. Moreover, human intervention studies should 
be performed. Here the IRMS analyses provide a very interesting tool to encourage 
stategies for prevention and therapy of obesity and its metabolic consequences 
particularly in postmenopausal women. Measurements of 15N/14N ratios enable to 
distinguish whether an organism is more in an anabolic or catabolic state (Huelsemann et 
al., 2009). Human urine and/or hair can serve as test material and can be taken easily. 
Moreover, based on the metabolic fluxes within a human body the appropriate level of 
physical activity as well as the influence of dietary isoflavones (e.g., soy milk) can be 
evaluated. 
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